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Antibacterial resistance is a natural biological phenomenon of response of bacteria to the 
selective pressure of an antibiotic. The overuse and misuse of antibiotics in humans and 
in animal husbandry has been cited as a responsible factor in the development of drug 
resistance in all bacterial species. Emergence of multidrug resistance is more worrisome 
in entire medical fraternity. Multidrug-resistant strains possessing extended spectrum P-
lactamases (ESBLs) has become an increasing problem worldwide. The advancing age, 
female gender, low socio economics status, illiteracy, hospital cross infection, the food 
chain trade and human migrations have contributed to increase the risk for community-
acquired ESBL. CTX-M, SHV, TEM, and OXA enzymes have become the most 
prevalent ESBLs. The work presented in this thesis has explored the susceptibility and 
resistance pattern of clinical isolates of hospital setting, risk factors for acquisition of 
these organisms, mode of spread of resistance, prevalence of ESBL producers among 
bacterial isolates of clinical origin and their molecular mechanism of resistance. 
The first chapter of this study was made to (i) characterize the bacterial pathogens 
in patients having gram negative septicemia, (ii) evaluate the bacterial resistance and (iii) 
explore the underlying molecular mechanisms in these strains. 70 cases of gram negative 
sepsis were included in this prospective, open labeled, observational study. Standard 
methods for isolation and identification of bacteria were used. Antimicrobial 
susceptibility and ESBL testing was performed by the standard disc diffusion method. 
PCR amplification was performed to identify Wacrx-M, A/tfsHv and WaxEM type ESBLs. 
Conjugation experiment was performed to show resistant marker transfer. The most 
prevalent isolates E. coli 58.6%, Klebsiella spp. 32.9% and Pseudomonas 8.6%, were 
resistant to most of the antimicrobials including cefazolin, ceftriaxone, cefiiroxime, 
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ampicillin and co-trimoxazole but sensitive to imipenem and meropenem. ESBL and 
MBL production was seen 7.3% and 12.2% of E. coli isolates, respectively. Three 
isolates were found to have A/«CTX-M-I5 and two of them also showed WarEM-i type 
enzymes. Whereas, none of them was observed to possess blamv- Conjugation 
experiments using J-53 cells confirmed these resistant markers as plasmid mediated. The 
study highlights the molecular epidemiology of escalating antimicrobial resistance and 
likely switch over of blacrx-M-is type extended spectrum ^-lactamases by WOTEM type 
ESBLs in India. Further, the antimicrobial resistance by horizontal gene transfer was 
predominant among Enterohacteraceae in the community setting. 
Second chapter of this study was designed to (i) find out the susceptibility of 
antimicrobial agents, (ii) identify the various risk factors associated with ESBL producing 
K. pneumoniae clinical isolates, and (iii) understmid the mode of mechanism among the 
K. pneumoniae isolates circulating in neonatal intensive care unit (NICU), Aligarh 
hospital of North India. Clinical isolates were characterized to detect K. pneumoniae. 
Susceptibility testing was done by standard disc diffusion method. MIC was determined 
using agar dilution methods. ERIC-PCR and resistant marker detection was performed by 
PCR amplification. Plasmid analysis and transfer experiments were carried out to fiirther 
type the strains. Sequence analysis of resistant marker (W«CTX-M, A/«TEM and A/ASHV) was 
performed. Incompatibility and multilocus sequence typing were carried out. Among the 
clinical isolates, 103 (37.62%) strains were identified as extended spectrum ^-lactamase 
producing Klebsiella pneumoniae (EPK) while remaining 262 (71.78%) strains were non-
EPK. Furthermore, 103 EPK strains were characterized according to socioeconomic 
status, educational status, gestational age, onset sepsis, birth weight, maternal intrapartum 
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symptomatic infection, prolonged rupture of membrane, infection carriage, length of stay 
in NICU and environmental origin. EPK were found susceptible to carbapenem, 
cephalosporins, gatifloxacine and amikacin. PCR amplification and sequence analysis 
revealed bhcrx-M-i, blttiEtA-i and blasuv-i as predominant markers in EPK. PCR based 
replicon typing revealed Inc/FIC, Inc/H12, Inc/X and Inc/FIB types of plasmids. MLST 
analysis showed prevalence of ST-64/51/280 among the EPK carrying CTX-M-3 type 
ESBL on Inc FIB/HI 2/FIC/X types of plasmids, indicating horizontal gene transfer. Low 
socioeconomic status, illiteracy of mother and instrumental carriage are independent risk 
factors for EPK infections. 
Third chapter of this study was aimed to characterize the mode of transmission of 
blacTx-M, blajEM, blasm, WfloxA-i, Arm-A and Rmt-A among extended spectrum P-
lactamases (ESBL) producing K. pneumoniae strains isolated from NICU of a teaching 
hospital of North India for understanding of molecular mechanism of resistance. 3000 
neonates admitted during January 2009 to February 2011 in NICU were screened for 
clinical isolates and characterized for K. pneumoniae. Susceptibility testing was done by 
standard disc diffusion method. MIC was determined using agar dilution methods. ERIC 
and replicon types were performed to type the strains. PCR amplification and sequence 
analysis of blacrx-M, blajEu, blasnv, W«OXA-I, Arm-A and Rmt-A were carried out. 
Plasmid analysis and transfer experiments were performed to understand the mode of 
transfer of resistant marker. 262(33.37%) isolates were characterized in NICU as ESBL 
producing K. pneumoniae strains. These ESBL producing K. pneumoniae strains were 
found susceptible only to carbapenem, cephalosporins and amikacin. PCR amplification 
and sequence analysis revealed blacrx-M, blttrsM, W«SHV, blaoxAi, Arm-A and Rmt-A as 
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predominant markers in ESBL producing K. pneumoniae strains. The plasmids carrying 
blacTx-M-i '^^ TEM-i, WflsHv-i, WaoxA-1, Arm-A and Rmt-A genes were assigned to Inc/11 y, 
Inc/FIA-FIB, Inc/FIB, Inc/HI2 and Inc/HIl types. Large genetic background diversity in 
the ESBLs producing isolates and dissemination of the biacrx-M, MOJEM, blasm, WAOXA-I, 
Arm-A and Rmt-A genes harboring isolates were observed within the ESBL producing 
K. pneumoniae strains of NICU of Aligarh, North India. This study revealed plasmid 
mediated resistance to ESBL producing J^ . pneumoniae. This study also suggests 
carbapenem, ceftazidime and amikacin as drugs of choice. 
The fourth chapter of this study aimed at (i) identifying the MBL producing 
bacterial isolates in infected diabetic foot ulcerated patient, (ii) determining and 
quantifying the resistance and susceptibility of those isolates, and (iii) characterizing the 
mode of transmission of CTX-M, TEM, SHV, NDM-1, VIM, OXA and Arm-A among 
the MBL producing clinical isolates. Twenty clinical isolates of infected diabetic foot 
patients fi-om ICU and endocrinology ward of a teaching hospital of North India were 
screened for MBL producing pathogens. Antimicrobial susceptibility and MBL detection 
were performed and reconfirmed with HiComb MIC testing strips and disk diffusion 
method. MIC was determined using agar dilution methods. PCR amplification and 
sequence analysis of 6/acrx-M» WOTEM, WOSHV, WaoxA-i, and Arm-A were carried out. To 
understand the mode of transfer of resistant marker, conjugational transfer method was 
used. Replicon typing and MLST were performed to type the strains. Insertion sequence 
was also identified. Out of 20 clinical isolates of diabetic foot ulcer, 14 strains were 
characterized as K. pneumoniae, 5 were E. coli and one was E. cloacae. One K. 
pneumoniae (Kpl2) and one E. cloacae (Eel 5) were also found to be carbapenem 
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resistance. PCR amplification and sequence analysis revealed the presence of NDM-1 in 
Kpl2, and Eel5 strains, blacxxxs, biasm-i in all clinical isolates, WATEM-I in 12 isolates 
(9 isolates in K. pneumoniae, 2 isolates in E. coli and one isolate in E. clocace) and 
WooxA-i in 7 isolates (5 isolates in K. pneumoniae, one isolate in E. coli and one isolate in 
E. clocace). Replicon typing revealed the /^ONDM-I carrying plasmid in Eel5 of 
incompatibility group Inc L/M. MLST analysis of Kpl2 showed ST14. Genetic 
environment revealed remnant of ISA6al25 upstream of the A/ONDM-I gene in Eel 5 and 
an entire ISAial25 upstream of the A/ONDM-I gene in Kpl2. Moreover, bleomycin 
resistance gene 6/eMBL was also identified downstream of the 6/aNDM-i gene in both the 
cases. This study reports the MBL producers having WaNOM-i gene in K. pneumoniae and 
E. cloacae isolate of diabetic foot ulcer and revealed the mode of transmission and 
mechanism of resistance of these isolates. 
The nucleotide sequences obtained in the thesis work appear in GenBank 
accession numbers as [GenBank: JN680194.1] and [GenBank: JN680195.1]. 
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Antibacterial resistance is a natural biological phenomenon of response of bacteria to the 
selective pressure of an antibiotic. The overuse and misuse of antibiotics in humans and 
in animal husbandry has been cited as a responsible factor in the development of drug 
resistance in all bacterial species. Emergence of muhidrug resistance is more worrisome 
in entire medical fraternity. Multidrug-resistant strains possessing extended spectrum p-
lactamases (ESBLs) has become an increasing problem worldwide. The advancing age, 
female gender, low socio economics status, illiteracy, hospital cross infection, the food 
chain trade and human migrations have contributed to increase the risk for community-
acquired ESBL. CTX-M, SHV, TEM, and OXA enzymes have become the most 
prevalent ESBLs. The work presented in this thesis has explored the susceptibility and 
resistance pattern of clinical isolates of hospital setting, risk factors for acquisition of 
these organisms, mode of spread of resistance, prevalence of ESBL producers among 
bacterial isolates of clinical origin and their molecular mechanism of resistance. 
The first chapter of this study was made to (i) characterize the bacterial pathogens 
in patients having gram negative septicemia, (ii) evaluate the bacterial resistance and (iii) 
explore the underlying molecular mechanisms in these strains. 70 cases of gram negative 
sepsis were included in this prospective, open labeled, observational study. Standard 
methods for isolation and identification of bacteria were used. Antimicrobial 
susceptibility and ESBL testing was performed by the standard disc difiusion method. 
PCR amplification was performed to identify Wacrx-M, W«SHV and blaj^M type ESBLs. 
Conjugation experiment was performed to show resistant marker transfer. The most 
prevalent isolates E. coli 58.6%, Klebsiella spp. 32.9% and Pseudomonas 8.6%, were 
resistant to most of the antimicrobials including cefazolin, ceftriaxone, cefuroxime, 
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ampicillin and co-trimoxazole but sensitive to imipenem and meropenem. ESBL and 
MBL production was seen 7.3% and 12.2% of E. coli isolates, respectively. Three 
isolates were found to have WACTX-M-IS and two of them also showed WaxEM-i type 
en2ymes. Whereas, none of them was observed to possess WASHV- Conjugation 
experiments using J-53 cells confirmed these resistant markers as plasmid mediated. The 
study highlights the molecular epidemiology of escalating antimicrobial resistance and 
likely switch over of Wflcrx-M-is type extended spectrum P-lactamases by WATEM type 
ESBLs in India. Further, the antimicrobial resistance by horizontal gene transfer was 
predominant among Enterobacteraceae in the community setting. 
Second ch^ter of this study was designed to (i) find out the susceptibility of 
antimicrobial agents, (ii) identify the various risk factors associated with ESBL producing 
K. pneumoniae clinical isolates, and (iii) understand the mode of mechanism among the 
K. pneumoniae isolates circulating in neonatal intensive care unit (NICU), Aligarh 
hospital of North India. Clinical isolates were characterized to detect K. pneumoniae. 
Susceptibility testing was done by standard disc diffusion method. MIC was determined 
using agar dilution methods. ERIC-PCR and resistant marker detection was performed by 
PCR amplification. Plasmid analysis and transfer experiments were carried out to fiirther 
type the strains. Sequence analysis of resistant maricer (A/acrx-M, W^TEM and WASHV) was 
performed. Incompatibility and multilocus sequence typing were carried out. Among the 
clinical isolates, 103 (37.62%) strains were identified as extended spectrum P-lactamase 
producing Klebsiella pneumoniae (EPK) while remaining 262 (71.78%) strains were non-
EPK. Furthermore, 103 EPK strains were characterized according to socioeconomic 
status, educational status, gestational age, onset sepsis, birth weight, maternal intrapartum 
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symptomatic infection, prolonged rupture of membrane, infection carriage, length of stay 
in NICU and environmental origin. EPK were found susceptible to carbapenem, 
cephalosporins, gatifloxacine and amikacin. PCR amplification and sequence analysis 
revealed A/«CTX-M-3, WOTEM-I and blasm-i as predominant markers in EPK. PCR based 
replicon typing revealed Inc/FIC, Inc/H12, Inc/X and Inc/FIB types of plasmids. MLST 
analysis showed prevalence of ST-64/51/280 among the EPK carrying CTX-M-3 type 
ESBL on Inc FIB/HI 2/FIC/X types of plasmids, indicating horizontal gene transfer. Low 
socioeconomic status, illiteracy of mother and instrumental carriage are independent risk 
factors for EPK infections. 
Third chapter of this study was aimed to characterize the mode of transmission of 
WocTX-M, bloTEM, WttsHV, WflQXA-i, Arm-A and Rmt-A among extended spectrum p-
lactamases (ESBL) producing K. pneumoniae strains isolated from NICU of a teaching 
hospital of North India for understanding of molecular mechanism of resistance. 3000 
neonates admitted during January 2009 to February 2011 in NICU were screened for 
clinical isolates and characterized for K. pneumoniae. Susceptibility testing was done by 
standard disc diffusion method. MIC was determined using agar dilution methods. ERIC 
and replicon types were performed to type the strains. PCR amplification and sequence 
analysis of MOCTX-M, A/^TEM, blasm, blooxA-i, Arm-A and Rmt-A were carried out. 
Plasmid analysis and transfer experiments were performed to understand the mode of 
transfer of resistant marker. 262(33.37%) isolates were characterized in NICU as ESBL 
producing K. pneumoniae strains. These ESBL producing K. pneumoniae strains were 
found susceptible only to carbapenem, cephalosporins and amikacin. PCR amplification 
and sequence analysis revealed biocrx-M, blojEM, biasnv, WaoxA-i, Arm-A and Rmt-A as 
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predominant markers in ESBL producing K. pneumoniae strains. The plasmids carrying 
WacTx-M-3 WtfTEM-i,*'flsHv-i.W«oxA-i,Arm-A and Rmt-A genes were assigned to Inc/Ily, 
Inc/FIA-FIB, Inc/FIB, Inc/HI2 and Inc/HIl types. Large genetic background diversity in 
the ESBLs producing isolates and dissemination of the blacrxM, WATEM, WflsHV,*/«oxA-i, 
Arm-A and Rmt-A genes harboring isolates were observed within the ESBL producing 
K. pneumoniae strains of NICU of Aligarh, North India. This study revealed plasmid 
mediated resistance to ESBL producing K. pneumoniae. This study also suggests 
carbapenem, ceftazidime and amikacin as drugs of choice. 
The fourth chapter of this study aimed at (i) identifying the MBL producing 
bacterial isolates in infected diabetic foot ulcerated patient, (ii) determining and 
quantifying the resistance and susceptibility of those isolates, and (iii) characterizing the 
mode of transmission of CTX-M, TEM, SHV, NDM-1, VIM, OXA and Arm-A among 
the MBL producing clinical isolates. Twenty clinical isolates of infected diabetic foot 
patients from ICU and endocrinology ward of a teaching hospital of North India were 
screened for MBL producing pathogens. Antimicrobial susceptibility and MBL detection 
were performed and reconfirmed with HiComb MIC testing strips and disk diffusion 
method. MIC was determined using agar dilution methods. PCR amplification and 
sequence analysis of blocrx-u, WajEM, blosnv, blaoxA-\, and Arm-A were carried out. To 
understand the mode of transfer of resistant marker, conjugational transfer method was 
used. Replicon typing and MLST were performed to type the strains. Insertion sequence 
was also identified. Out of 20 clinical isolates of diabetic foot ulcer, 14 strains were 
characterized as K pneumoniae, 5 were E. coli and one was E. cloacae. One K. 
pneumoniae (Kpl2) and one E. cloacae (Eel5) were also found to be carbapenem 
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resistance. PCR amplification and sequence analysis revealed the presence of NDM-1 in 
Kpl2, and Ecl5 strains. Wacrx-is, W«SHV-I in all clinical isolates, WATEM-I in 12 isolates 
(9 isolates in K. pneumoniae, 2 isolates in E. coli and one isolate in E. clocace) and 
blooxA-i in 7 isolates (5 isolates in K. pneumoniae, one isolate in E. coli and one isolate in 
E. clocace). Replicon typing revealed the A/ONDM-I carrying plasmid in Eel5 of 
incompatibility group Inc L/M. MLST analysis of Kpl2 showed ST 14. Genetic 
envirormient revealed remnant of ISAZ>al25 upstream of the WONDM-I gene in Eel5 and 
an entire ISA6al25 upstream of the /^ONDM-I gene in Kpl2. Moreover, bleomycin 
resistance gene W^MBL was also identified dovmstream of the A/ONDM-I gene in both the 
cases. This study reports the MBL producers having blotnm-x gene in K pneumoniae and 
E. cloacae isolate of diabetic foot ulcer and revealed the mode of transmission and 
mechanism of resistance of these isolates. 
The nucleotide sequences obtained in the thesis work appear in GenBank 
accession numbers as [GenBank: JN680194J] and [GenBank: JN680195.1]. 
XII 
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1.1 Antibiotics: 
1.1.1 Definition and characteristics of antibiotics 
Antibiotics are antibacterial substance produced by various species of microorganism that 
suppress the growth of or kill other microorganism at very low concentration and have no 
or minimal effect on recipient. Common usage often extends the term antibiotics to 
include synthetic antimicrobial agents, such as sulfonamides and quinolones that also 
inhibit microorganism. Antibiotics differ markedly in physical, chemical, and 
pharmacological properties, in antimicrobial spectra, and in mechanism of action. 
Knowledge of molecular mechanism of bacterial replication has greatly facilitated 
rational development of compounds that can interfere with their replication. 
1.1.2 Historical perspective 
Antimicrobial drugs are greatest contribution of the 20* century to therapeutics. In earlier 
times, peoples were using indigenous substances in the treatment of infective disease, but 
both, physicians and patients, were unaware with the basis and mechanism of action of 
therapeutic agents. Ancient medicines have a long list of anti-protozoa drugs to cure the 
protozoan diseases and few for bacterial diseases like mercury and its compound for 
syphilis. Discoveries of microbes mediated pathology explored the pathway for its 
elimination in the terms of antimicrobial agents. In early 17* century, extract of cinchona 
bark (quinine) and ipecacuanha root (emetine) were identified and used as anti-malarial 
and anti-amoebic agents respectively [Garrod et al, 1971; Greenwood et al, 2000]. Paul 
Ehrlich, in early nineteoith century, has reported that dyes due to their differential 
affinities for various tissues may be used as antimicrobial agent. In 1904, the work of 
Ehrlich and Shiga has attracted the entire scientific world as they explored the usefulness 
and effectiveness of red dye called trypanrot against trypanosomes. [Mitsuhashi et al, 
1993]. In 1909, Ehrlich along with Sahachiro Hata observed that arsphenamine (named 
Salvarsan) is active against spirochetes and, therefore, very soon it become an effective 
anti syphilitic agent [Greenwood et al, 2000]. 
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Sulphonamides were the first antimicrobial drugs which were discovered by Gerhard 
Domagk [Domagk et al, 1935]. Mietzsch and Klarer of Bayer Company synthesized 
Prontosil red, a red dye that binds to a sulfonamide group and later it was found by 
Domagk pomagk et al, 1935] to be an effective agent against hemolytic streptococci in 
mice. [Garrod et al, 1971; Greenwood et al, 2000]. Though, in vifro studies, prontosil 
red was shown to have no antibacterial activity. But later prontosil red was found to be an 
effective antimicrobial agent as it split into its component dye and an active antibacterial 
molecule, sulfanilamide that was already in tiie public domain [Trefouel et al, 1935]. 
Idea of using the microbes as therapeutic agent was not new among the scientific world. 
Penicillin was the first to be discovered as natural antibiotics. An extract oi Pseudomonas 
aeruginosa known as pyocyemase was in use for the treatment of wounds. [Garrod et al, 
1971]. Raper and Fennel introduced [Raper et al, 1946] a strain of Penicillium 
chrysogenum producing higher yiled of penicillin [Demain et al, 1999]. 
Discovery of penicillin became a mile stone for the discovery of many antimicrobial 
agents. Soil microorganisms were also taken by Selman Waksman (1940) for discovery 
of antibiotic molecule [Greenwood et al, 2000]. And one of his students in 1943 got 
success to find out the new antimicrobial agent, streptomycin [Schatz et al, 1944]. In 
same period, Rene Dubos [Hotchkiss et al, 1941] identified a new molecule gramicidin, 
the first antibiotic active against gram-positive bacteria. And shortly thereafter, 
chlortetracycline, chloramphenicol, and some other molecules were discovered [Garrod 
et al, 1971]. Among the identified and discovered molecules, many of them were found 
to be toxic but these discoveries lead to the development of more rational molecules and 
within only 10 years, drugs comprising the major classes of antibiotics were identified 
and developed [Greenwood et al, 2000]. Majority of these molecules were identified and 
isolated fix)m antibiotics producing microorganisms of interesting and unusual sources 
like wounds, sewage, a chicken's throat, and a wet patch of wall in Paris [Garrod et al, 
1971]. Nalidixic acid, a synthetic drug, was the first of the quinolones to be identified and 
though it was not therapeutically importmit but modification of nalidixic acid led to the 
production of the highly effective fluoro-quinolones. Members of this class, such as 
ciprofloxacin, norfloxacin, enorfloxacin, gatifloxacin and ofloxacin, have become very 
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important in the treatment of diseases in both humans and animals [Mitsuhashi et al, 
1993]. 
In sixth decade of twentieths century, after the discovery of few antibiotics, drugs 
development of antibiotics become a merely chemical modifications of existing drugs. 
These modifications are found to be quite useful and are capable to enhanced killing of 
pathogens and have a broad spectrum action. They are also attributed with lesser side 
effects [Lipsitch et al, 2002]. Recently, combination of drugs for antibiotic therapy is 
introduced by clinician to overcome the drug resistance problem. The approach in 
combination drug therapy seems to be permissible as it has different mechanisms of 
action and enhanced effectiveness. 
1.13 Susceptibility and resistance of antimicrobial agents 
Successful antimicrobial therapy of an infection uhimately depends on the concentration 
of antibiotic at the site of infection. This concentration must be sufficient to inhibit 
growth of the offending micro-organisms. If host defenses are intact and active, a 
minunum inhibitory effect such as that provided by bacteriostatic agents may be 
sufficient. On the other hand, if host defenses are impaired, antibiotic mediated killing 
may be acquired to eradicate the infection. The concentration of drug at the site of 
infection not only inhibits the organism but also remain below the level that is toxic to 
human cell. If this can be achieved, the microorganism is considered susceptible to the 
antibiotics. The achievable serum concentration for an antibiotic, guides of break point 
for designating a microorganism as either susceptible or resistant by in vitro susceptibility 
testing. However, the concentration at the site of infection may be considerably lower 
than achievable serum concentratimi (e.g. various fluids of the eye at CSF). Local factors 
e.g. low pH, high concentration, and anaerobic conditions may also impair drug activity. 
Thus, the drug may be effective or ineffective in such cases even though standardized in 
vitro test would likely report the microorganism as sensitive. Conversely, concentration 
of drug in urine may be much higher than those in plasma. Microorganism that might 
otherwise be considered "resistant" may be eradicated when infection is limited to 
urinary tract. 
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1.1.4 Antibiotic failure: the leading therapeutic challenge 
The recent emergence of antibiotic resistance in bacterial pathogens, both nosocomially 
md in community acquired is very serious development that threatens the end of the 
antibiotic era. Today, more than 70% of the bacteria associated with hospital acquired 
infections in United States are resistant to one or more of the drugs previously used to 
treat them. Bacterial resistance renders therapy more costly and sometimes patients may 
succumb to resistant orgmism due to fakire of all avail^le antibiotics [Levy & 
Marshall., 2004]. Enteric disease agents such as Salmonella enteritidis. Shigella flexneri 
and Vibrio spp, especially, in developing countries, found to be muhi drug resistant and 
become a challenge for public health. Penicillin-resistant strains of pneumococci account 
for 50% or more of isolates in some European countries, and the i»oportion of such strain 
is rising in the United States. Increasing pneumococci resistance led a worldwide threat in 
treatment of pneumonia and ear infections. Recent reports of microbial resistance to 
macrolides and tetracyclines exposed the susceptibility of these antimicrobial agents 
[Schrag et al. 2004}. The world wide emergence of Haemophilus, and gonococci that 
produce p-lactamase is major therapeutic problem. Methicillin-resistant strains of 
staphylococcus aureus are endemic in hospital and are isolated increasingly from 
community-acquired infections P^ Jaimi et al, 2003; Vandenesh et al., 2003]. In US and 
UK, 40-60% of nosocwnial S. aureus strains are found to be methicillin-resistant 
(MRSA), and usually MDR [Weinstein et al.. 2001; Anonymous et al., 2002]. Higher 
mortality rate are usually associated with MRSA as compared to methicillin-sensitive 
strains [Cosgrove et al., 2003]. Some MRSA also showed low level resistance to drug of 
choice vancomycin [Hiramatsu et al., 1998, Fridkin et al.. 2001]. Acquired vancomycine 
resistant S.aureus strains from vancomycin resistant enterococci have been observed in 
US [Weigel et al., 2003; Tenover et al., 2004]. Some strains of methicilin and 
vancomycin-resistant S. aureus have also emerged as resistant to linezolid and the 
streptogramin combination, dalfopristin/quinopristin [Jones et al., 1998; Meka & Gold et 
al., 2004]. In developed countries, MRSA strains possessing a new virulence toxin 
(Panton-Valentine leukocidin) have been emerged as resistant to p-lactam antibiotics 
[Vandenesch et al., 2003; Herold et al., 1998]. The failures of antibiotics therapy in 
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MRSA infection render to bring an alternative therapy when MRSA is suspected as 
disease had become too far advanced [Anonymous et al, 1999]. Multi-drug resistance 
strains of S.aureus with intermediate susceptibility to antibiotics and high level resistance 
to vancomycin have been reported [Hiramatsu et.ai, 1997; smit et.al., 1999, weigel et. 
al., 2003]. The emergence of multidrug resistant stmns of Gram-negative bacteria 
{Pseudomonas, Klebsiella, Enterobacter, Acinetobacter, Salmonella species,) and Gram-
positve organisms {Staphylococcus, Enterococcus, Streptococcus species) is more 
worrisome in the present therapeutic scenario. Among the Enterobacteriaceae, P-
lactamases producers, Enterobacter and Klebsiella are found to inactivate the latest 
generation of penicillins and cephalosporins [Bush et al, 2001; Bradford et al, 2001]. 
Some strains of enterobacteriaceae bearing metallo-p-lactamases are also observed to be 
resistant to carbq)enems [Nordmann & Poirel., 2002; Livermore & Woodford., 2000]. 
E.coli strains, a common cause of urinary tract infection, have been found to be 60-70% 
resistant to the majority of drug families including fluoroquinolones especially in 
Southeast Asia and China, and also in US and UK [Jones, R.N. et al 1998; Meka, V.G. 
& Gold, H.S. 2004]. This trend of resistance jeopardizes the worth of this drug [Zervos et 
al, 2003; Karlowsky et al, 2002]. Many patients of tuberculosis are remained untreated 
due to resistant M. tuberculosis to all anti-tubercular drugs [Bloom & Murray., 1992]. 
hiadequate treatment of tuberculosis increases risk of bacterial resistance, and more than 
50% of such individuals have MDR tuberculosis. Epidemics of multi drug resistance 
strains of Mycobacterium tuberculosis have been reported in the United States. 
Worldwide physicians are facing the problem of penicillins, tetracyclines and 
fluoroquinolones resistance in N. gonorrhoeae [Tanaka et al, 2000; Anonymous et al, 
2002]. Parenteral cq}halosporin is only treatment as a single dose therapy to infected 
individuals with this pathogen, but, a recent report showing the decreased susceptibility 
of cefixime to N. gonorrhoeae warns the fiiture of this group of drugs [Wang et al, 
2003]. The study predicted about the encumbered community with MDR organism that, 
multidrug resistance will override single-drug resistance in the {vesent decade 
[McCormick et al, 2003]. Resistance problem in community indicates that resistant 
strains can be traced from the community to the hospital and vice versa, indicating that 
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drug resistance is no longer localized as resistance in the community and has extended 
the resistance beyond the hospital premises. 
1.1.5 Classification and mechanism of action of antimicrobial agents 
Antimicrobial agents are calssified based on chemical structure and proposed mechanism 
of action as follows: (1) agents that inhibit synthesis of bacterial cell walls, including the 
^lactam class (e.g. penicillin, cephalosporins, and carbapenems) and dissimilar agents 
such as cycloserine, vancomycin, and bacitracin; (2) agents that act directly on the cell 
membrane of microorganism, increasing permeability and leading to leakage of 
intracellular compounds, including detergents such as polymyxin; polyene antifimgal 
agents (e.g.amphotericin B) which binds to cell wall sterols; and the lipopeptide 
daptomycin [Carpenter and Chambers., 2004]; 
Table 1.1 Major classes of antibiotics 
Protein 
synthesis 
Nucleic acid 
synthesis 
Cell wall 
synthesis 
Aminoglycosides Chloramphenicol 
Streptomycn 
Neomycin 
Kanamycin 
Gentamidn 
Su4>honsHnides (Diaminopyrimidbies) 
Sulfemethoxazole trimethoprim 
P-Jactams 
Penidliins 
Cephalosporins 
Carbapenems 
Teb'acyclines Macrolides 
Eiythromycin 
Azythromycin 
Clarithromycin 
Quholones 
Ciprofloxacin 
Norfloxacin 
Glycopeptides 
Vancomycin 
Avopuricm 
Streogramins 
Virginiamycin 
Quinopristin 
Dalfopristin 
Pristinamycin 
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(3) agents that disrupt function of 30S or 50 S ribosomal subunit to reversibiy inhibit 
protein systhesis, which generally are bacteriostatic (e.g. choloamphenicol, the 
tetracyclines, erythromycin, streptogramins, clindamycin and linezolids);(4) agents that 
binds to BOS ribosomal subunit and later protein systhesis, which genrally are bactericidal 
(e.g. aminoglycosid); (5) agents that affect the bacterial nucleic acid metabolism, such as 
the rifamycin (e.g. rifampin and rifabutin), which inhibit RNA polymerase, and the 
quinoiones, which inhibit topoisomerases and (6) the antimetabolites, including 
trimethoprim and sulfonamides, which block essential enzymes of folate metabolism. But 
broadly it may be classified and understood under following three major groups (Table-
1.1). 
a. Inhibition of cell wall synthesis 
P-lactams and glycopeptides are most important bacterial cell wall synthesis inhibitors. 
They are frequently prescribed antimicrobial agents sharing a common structure and 
mechanism of action i.e. inhibition of bacterial peptidoglycan cell wall synthesis. Since, 
bacterial cell walls are wholly unlike the membranes of eukaryotes, therefore, they are an 
obvious target for selectively toxic antibiotics, p-lactams includes penicillins, 
cephalosporins, and the carbapenems. These agents bind to the penicillin binding proteins 
(PBP's) that cross-link strands of peptidoglycan in the cell wall. In gram negative cells, 
this leads to the formation of fragile spheroplasts that are easily ruptured. In gram 
positive cells, autolysis is triggered by the release of lipoteichoic acid. 
Chromosomally encoded ^-lactamases enzymes are found in many bacteria that are 
necessary for cell wall production. But, when production of these enzymes increases, it 
inactivates p-lactam antibiotics by hydrolyzing of P-lactam ring and thus producing the 
resistance [Greenwood et al, 2000]. ^-lactamases encoded by plasmids or other 
transmissible elements can lead to such overproduction and, therefore, to resistance 
[Normark & Normark, 2002]. Alteration in PBPs may also results in reduced penicillin 
binding and, hence, resistant [Greenwood et al, 2000]. Aftw the discovery of penicillin 
and bacterial resistance, many new molecules of the ^lactams have been developed and 
clinically used. These new molecules having different spectrums of activities have 
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different susceptibility to ^lactamases. Clavulanic acid has the ability to bind irreversibly 
to P-lactamases and, thereby, inhibit their action. Drug combinations of this type of 
molecule with p-lactam have been proved useful in treatment of several pathological 
conditions [Bryan et al, 1984]. 
Glycopeptides are a group of antibiotics that include vancomycin, avoparcin etc, which 
bind to acyl-D-alanyl-D-alanine. Binding of this compound prevents the addition of new 
subunits to the growing peptidoglycan cell wall, thus limiting their action to gram 
positive organisms. Earlier, resistance to glycopeptide was thought to be rare, but has 
recently been shown to be quite common [Bryan et al, 1984]. Resistance in Enterococci 
has developed through newly discovered enzymes that use D-alanyl-D-lactate in place of 
acyl-D-alanyl-D-alanine, allowing cell wall synthesis to continue. Other mechanisms of 
resistance involve the over-production of peptidoglycan precursors which overwhelm the 
drug [Greenwood et al, 2000]. 
b. Inhibitors of protein synthesis 
Various groups of antibiotics are responsible for inhibition of bacterial protein synthesis. 
The aminoglycoside groups is broadly divided into three major groups; streptomycins, 
neomycin, and kanamycin. Through active transport system in bacteria, antibiotics enter 
in bacterial cells with the help of quinolones that are absent in anaerobes and 
streptococci, making them unavailable for pharmacological action of these agents. 
Aminoglycosides irreversibly binds to 16S rRNA and block the initiation complex. By 
binding to 16S rRNA the aminoglycosides increase the affinity of the A site for tRNA 
regardless of the anticodon specificity. Streptomycins have the affinity to bind with the 
30S ribosomal subunit while kanamycin and neomycin with SOS subunit as well as with 
sites on 308 subunit in unique maimer that is different from streptomycin and thus 
produce their effect [Greenwood et al, 2000]. Drugs after binding with their sites, start 
their activity by involving initiation complexes and cell membrane proteins that 
contribute to cell death and plays a role in the action of these antibiotics, but this is poorly 
understood [Bryan etal, 1984; Greenwood etal, 2000]. 
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Amioi^lycoside resistance mechanism include: (a) the deactivation by N-acetylation, 
adenylation or 0-phosphorylation (b) the reduction of the intracellualar concentration of 
aminoglycosides by changes in outer membrane permeability, decreased inner membrane 
transport, active efflux, and drug trapping, (c) the alteration of 308 ribosomal subunit 
target by mutation, and (d) methylation of the aminoglycoside binding site [Shakil et al, 
2008; Bryan e/a/., 1984]. 
Chloramphenicol, naturally occurring fix>m Streptomyces venezuelae, is a broad-
spectrum antibiotic and produced by chemical synthesis. Chloramphenicols inhibit 
protein synthesis in bacteria and to lesser extent in eukaryotic cell. It also inhibits peptide 
bond formation on 70S ribosomes [Bryan etal, 1984]. This drug is especially useful as it 
can penetrate bacterial cell, eukaryotic cells and cerebrospinal fluid probably by passive 
diffusion, making it a drug of choice for treatment of meningitis and intracellular 
bacterial infections. But its use is very limited due to fatal side-effect i.e aplastic anemia 
[Greenwood et al, 2000]. 
Resistance to chloramphenicol usually is caused by a plasmid encoded chloramphenicol 
acetyltransferase enzyme that inactivates the drug. A number of these enzymes have been 
discovered, each altering the chloramphenicol molecule to prevent binding to the 
bacterial ribosome. Resistance to chobamphenicol in gram negative cell can also results 
from decreased permeability due to alteration in outer membrane that prevent the drug 
from entering the cell and also from ribosomal mutation [Bryan et al, 1984]. 
The tetracyclines are another group of broad-spectrum antibiotics that inhibit bacterial 
protein synthesis by binding to the 30S bacterial ribosome and preventing access of 
aminoacyl tRNA [Roberts et al, 1996]. They are brought into the cell of gram-negative 
bacteria by passive difiusion through hydrophilic channels formed by the porin proteins 
of the outer cell membrane and by active transport that pumps all tetracyclines across the 
cytoplasmic membrane. Entry of these drugs in to gram-positive bacteria requires 
metabolic energy but it is not well understood. 
Resistance to tetracycline is often plasmid mediated and often is inducible. The three 
main mechanisms are: (1) production of a membrane efflux pump that removes the drug 
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as rapidly as it enters and there are several genes encoding these pumps; (2) production of 
several ribosomal protection proteins that displace the tetracycline from binding to the 
ribosome, (3) a protein found only in Bacteroides ^p. , enzymatically inactivates 
tetracycline [Roberts et al, 1996]. Interestingly, efflux pump inhibitors have recently 
been discovered that may allow combinations of these inhibitors and tetracyclines to be 
used against previously resistant strains [Chopra et al, 2002]. 
Macrolides antibiotics contain a many-membered lactone ring to which are attached one 
or more deoxy sugar. They are commonly used to treat gram positive and intracellular 
bacterial pathogens. Erythromycin was the first of these, and several other important 
macrolides have been discovered since, including clarithromycin and azithromycin. It 
was originally believed that erythromycin inhibited protein synthesis by competing with 
amino acids for ribosomal binding sites, but newer research shows that several 
mechanisms are involved [Garrod et al, I97I]. The macrolides are now believed to 
promote dissociation of tRNA from the ribosome, inhibit peptide bond formation, inhibit 
ribosome assembly, and prevent amino acid chain elongation [Gaynor et al, 2003]. 
Resistance to macrolides usually results from one of four mechanisms: (1) drugs efflux 
by an active pump mechanism that removes the drug from the cell; (2) modification of 
the ribosome by inducible or constitutive production of methylase eiwymes that decrease 
the drug binding; (3) macrolide hydrolysis by easterases produced by 
Enterobacteriaceae; and (4) chromosomal mutation that alter SOS ribosomal protein and 
allosterically prevent macrolide binding. A common alteration is dimethylation of one 
nucleotide on the 23S rRNA that does not only prevents macrolide binding, but also 
confers resistance to lincosamide and streptogramin antibiotics [Gaynor et al, 2003]. 
The streptogramins are another class of protein synthesis inhibitors that inhibits protein 
synthesis mostly in gram positive organisms probably due to decreased permeability of 
their outer membrane. These antibiotics are actually combinations of structurally 
different drugs, types A and B that act synergistically. These compounds bind to separate 
sites on the SOS subunit Type A drugs block attachment of substrates at two sites on the 
SOS subunit, whereas type B drugs cause release of incomplete protein chains. The 
synergistic effect arises from a conformational change induced by the binding of a type A 
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drug which significantly increases affinity of type B drugs [Johnston et al, 2002]. 
Streptogramins which are currently in use include virginiamycin, pristinamycin, and 
quinupristin/dalfopristin. 
Resistance to streptogramin antibiotics can be found in several forms. Efflux pumps for 
both type A and B streptogramins have been identified. Type A streptogramins can be 
inactivated by one of the virginiamycin acetyl-transferases, and several enzymes have 
been identified that can inactivate type B streptogramins. Alteration of bacterial 
ribosomal proteins or RNA can also confer resistance. A common mutation is the 
dimethylation of one nucleotide on the 23S rRNA, mentioned previously, that gives rise 
to resistance to type B drugs, as well as macrolides and lincosamides [Johnston et al, 
2002]. 
c. Inhibitors of nucleic acid synthesis 
The introduction of diaminopyrimidines in combination with sulfonamide constitute an 
important advance in the development of clinically efTective antimicrobial agents and 
represents the practical application of a theoretical consideration; i.e if two drugs act on 
sequential steps in the pathway of an obligate enzymatic reaction in bacteria, the result of 
their combination will be synergistic. Although both types of drugs are useful on their 
own, they exhibit a synergistic effect when combined. Sulfonamides are currently not 
used commonly in medicine, but the combination drug trimethoprim-sulfamethoxazole is 
sometimes used in the treatment of urinary tract infections. The sulfonamides and the 
diaminopyrimidines indirectly inhibit the nucleic acid synthesis by inhibiting folate 
systhesis. Folate is a coenzyme required in synthesis of purines and pyrimidines. 
Sulfonamides serve as an analog of p-aminobenzoic acid. Therefore, they competitively 
inhibit an early step in folate synthesis. Diaminopyrimidines, of which trimethoprim is 
the most conmion, inhibit dihydrofolate reductase, the enzyme that catalyzes the final 
step in folate synthesis [Greenwood et al, 2000]. 
Microorganisms employ several resistance mechanisms against each of the anti-folate 
drugs. For example, sulfonamides are rendered ineffective by over-production of p-
aminobenzoic acid or production of an altered dihydropteroate synthetase. The substrate 
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for dihydropteroate synthetase is p-aminobenzoic acid, and the altered form has a much 
lower affinity for sulfonamides than for p-aminobenzoic acid [Then et al, 1982]. 
Trimethoprim resistance can also result fix)m several mechanisms, e.g., over-production 
of dihydrofolate reductase or production of an altered, drug-resistant form can lead to 
resistance [Bryan et al, 1984]. In addition, both drugs can be enzymatically inactivated, 
resulting in resistance [Then et al, 1982]. 
The quinolones; ciprofloxacin, norfloxacin, moxifloxacin, gatifloxacin and nalidixic acid, 
are a chemically varied class of broad-spectrum antibiotics widely used to treat many 
diseases, including gonorrhea and anthrax. Among the quinolones, ciprofloxacin is more 
used in clinical practices than any other antibacterial agent [Acar et al, 1997]. 
Quinolones antibiotics target bacterial DNA gyrase and topoisomerase IV, which are 
necessary for correct functioning of supercoiled DNA and thus inhibit their bacterial 
growth [Greenwood et al, 2000]. In many gram positive organisms, topoisomerase IV is 
inhibited by the quinolones. In contrast, for many gram negative bacteria, DNA gyrase is 
the primary quinolone target [Ruiz et al, 2003]. 
Several mechanisms of resistance to quinolones have been described. However, three 
most important mechanisms of resistance to quinolones have been established. Decreased 
expression of membrane porins leads to resistance in some quinolones. Cross-resistance 
to other drugs requiring these porins for activity also results from these changes. A 
second mechanism of resistance to quinolones is expression of efflux pumps in both gram 
negative and gram positive organisms [Novak et al, 1999]. And the third is the alteration 
of the target enzymes. Several mutations in bacterial chromosomal genes encoding DNA 
gyrase or topoisomerases IV has also been reported Aat may result in reduced binding 
afiinities [Ruiz et al., 2003]. It is believed that series of successive mutation in the target 
genes, rather tiian single mutation, is reqwnsible for high-level quinolone resistance 
[Novak e/a/., 1999]. 
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1.2 Drug resistance 
1.2.1 Mechanisms of antibiotics resistance 
Structural difference of eukaryotic and prokaryotic cells at cellular level is the key factor 
for differential selective toxicity of antibiotics and this structural difference among 
bacterial species can lead to resistance to certain antibiotics. The differences between 
intrinsic and acquired resistance to an antibiotic are also important for research as well 
therapeutic purposes. Intrinsic resistance that indicates the resistance of entire species to 
antibiotics is only because of inherent characteristics requiring without any genetic 
alteration. Many organisms are intrinsically resistant to a particular drug or molecule 
because they lack the target site of that durg or molecule. For example, Mycoplasma are 
always resistant to ^-lactam antibiotics as they are lacking of peptidoglycan (which the P-
lactams act upon). Many drug molecules, in case of gram negative organism, are unable 
to reach their target site. Pseudomonas aeruginosa has drug efflux pump and thus restrict 
the outer membrane permeability and thereby exhibiting high intrinsic resistance to many 
antibiotics. Acquired Resistance that arises through mutation or horizontal gene transfer 
is well established phenomenon in drug resistance. Generally, bacterial resistance to 
antimicrobial agent is attributed to three mechanisms; (1) the drug does not reach its 
target, (2) the drugs are not active, or (3) the target is altered [Davies et al, 1994; Spratt 
et al, 1994; Li & Nikaido, 2004]. The outer membrane of gram negative bacteria is a 
permeable barrier that excludes large molecules from entering the cell. Small polar 
molecules, including many antibiotics, enter the cell through protein channel called 
porins. Absence of mutation, or loss of favored protein channel can slow the rate of drug 
entry into cell or prevent entry altogether, effectively reducing drug concentration at 
target site. If the target is intracellular and the drug requires active transport across the 
cell membrane, a mutation or phenotypic change that shut down this transport mechanism 
can confer resistance as observed in the case of gentamicin resistance. Bacteria also have 
efflux pumps that can transport drugs out of the cell. Resistance to numerous drugs, 
including tetracycline, chloramphenicol, fluoroquinolone, macronilides, and P-lactam 
antibiotics, is mediated by an efflux pump mechanism [Li & Nikaido, 2004]. Drug 
13 
Saeedut Zafar AU, 2012 I Chapter-1 
inactivation is the second general mechanism of drug resistance. Bacterial resistance to 
aminoglycosides and to P-lactam antibiotics usually is due to production of an 
aminoglycoside-modifying enzyme or p-lactamase, respectively. A variation of this 
mechanism is failure of the bacterial cell to activate a prodrug. This is the basis of the 
most common type of resistance to isoniazide in M. Tuberculosis [Bertrand et al, 2004]. 
The third general mechanism of drug resistance is target alteration. This may be due to 
mutation of natural target (e.g. Fluoroquinolne resistance), target modification (e.g. 
ribosomal protection type of resistance to macronilides and tetracyclines), or acquisition 
of resistant from the native, susceptive target (e.g. staphylococcal methicillin resistant 
caused by production of low-affinity penicillin-binding protein) [Nakajima et al, 1999; 
Hooper et al, 2002; Lim and Strynadka, 2002]. Drug resistance may be acquired by 
mutation and selection, with passage of trait vertically to daughter cell. For mutation and 
selection to be successful in generating resistance, the mutation cannot be lethal and 
should not appreciably alter virulence. For the trail to be passed on the original mutant or 
its progeny also must disseminate and replicate; otherwise, the mutation will be lost until 
it is rediscovered by some other mutant arising from within a wild type population. Drug 
resistance more commonly is acquired by horizontal transfer of resistance determinants 
from donor cell, often to another bacterial species, by transduction, transformation, or 
conjugation. Resistance acquired by horizontal transfer can disseminate rapidly and 
widely either by colonal spr^d of the resistant strain or by subsequent transfer to other 
susceptible recipient strains. Horizontal transfer of resistance offers several advantages 
over mutation selection. Firstly, the lethal mutation of an essential gene is avoided and 
the level of resistance in horizontal gene transfer is higher than that produced by 
mutation. Secondly, the changes acquired in the gene can still be transmitted vertically 
and can be mobilized and rapidly amplified within population by transfer to susceptible 
bacteria. Thirdly, the resistance gene can be eliminated when it no longer offers selective 
advantage to the organism [Murray et al, 1992]. 
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1.2.2 Mutation selection 
Mutation is the molecular basis for resistance to streptomycin (ribosomal mutation), 
quinolone (gyrase or totpisomerase IV gene mutation) rifampin (RNA polymerase gene 
mutation), and linezolid (ribosomal RNA mutation). This mechanism underlies all drug 
resistance in M Tuberculosis [Riska et ai, 2004]. Mutation may occur in the gene 
encoding (1) the target protein, altering its structure so that it no longer binds the drug; 
(2) a protein involved in drug transport; (3) a protein important for drug activation or 
inactivation, in the case of extended spectrum P- lactamase [Bush et al, 2001]; or (4) in a 
regulatory gene or promoter affecting expression of Ae target, a transport protein, or an 
inactivating enzyme. Mutations are not caused by drug exposure per se. Mutations are 
random events that confer a survival advantage to the organism when drug is present. 
However, certain drugs that induce the bacterial SOS system of DNA repair protein that 
accommodate potentially lethal stress ( e.g. fluoroquinolone) may facilitate resistance 
gene transfer or increase the mutation frequency by induction of error-prone polymerases 
[Goodman et al., 2002; Chopra et al., 2003; Beaber et al., 2004]. Any large population 
of antibiotic-susceptible bacteria is likely to contain rare mutants that are less susceptible 
than the parent. Through, sequential acquisition of more mutants, clinically siginificant 
resistance may emerge. High level resistance of E.coli to fluoroquinolone is due to 
accumulation of multiple additive mutions. In some instance, a single-step mutation 
results in a high degree of resistance. For example, a point mutation within the drug 
binding domain in the B subunit of bacterial RNA polymerase confers high level 
resistance to rifampin. 
1.23 Horizontal gene transfer 
Horizontal transfer of resistance genes is greatly facilitated by and is largely depend on 
the mobile genetic elements. The role of plasmid and transducing phages as carriers of 
resistance gene and transfer elements is discussed in more details below. Other mobile 
elements, transposable elements, integrons and genetic cassettes also participate in the 
process. Transposable elements are of three general types: insertion sequence, 
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transposons, and transposable phages; two of these, insertion sequence and transposon 
are important for resistance. Insertion sequence [Mahillon & Chandler., 1998] are short 
segment of DNA encoding enzymatic function (e.g. transposases and resolvases) for site 
specific recombination with inverted repeat sequence at either end. They can copy 
themselves as insert themselves into the chromosomes or a plasmid. Insertion sequence 
does not encode resistance, but they function as sites for integration of other resistance-
encoding elements, e.g. plasmid or transposons. 
(a) Trasnsposons are basically insertion sequence that also code for other Unctions, one 
of which can be drug resistance. Since transposons move between chromosome and 
plasmid, the resistance gene can hitchhike its way onto a transferable element out of the 
host and into recipient. Transposons are mobile element that excise and integrate in 
bacterial genomic or plasmid DNA (i.e. from plasmid to plasmid, plasmid to 
chromosome, or from chromosome to plasmid). 
(b) Integrons are not formally mobile and do not copy themselves, but they encode an 
integrase and provide a specific site into which mobile gene cassettes can be integrated. 
Gene cassettes encode resistance determinants, usually lacking a promoter, with 
downstream repeat sequence. The integrase recognizes this repeat sequence and direct 
insertion of cassettes into position behind a strong promoter that is present on integron. 
Integrons may be located within transposons or in plasmids, and therefore may be 
mobilized, or located on the chromosome [Fluit & Schmitz., 2004]. Another type of gene 
cassettes, SCCmec (Staphylococcal Chromosomal Cassettes), has been described in 
methicilline-resistant strains of staphylococci [Katayama et ai, 2000]. The methicUin 
resistance gene mecA is located within this cassette along with recombinase gene. The 
recombinases both excise and integrate the cassette element, which exist as a circular 
intermediate that is not self replicating, into a very specific site in the staphylococcal 
chromosome. How this element is transferred and the role of exicision-mobilisation in 
this process is not known. 
(c)Traasduction is process of acquisition of bacterial DNA from a phage (a virus that 
propagates in bacteria) that has incorporated DNA from a previous host bacterium within 
its outer protein coat. If the DNA includes a gene for drug resistance, the newly infected 
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bacterial cell may acquire resistance. Transduction is particularly important in the transfer 
of antibiotics resistance among strains of 5. aureus. 
(d) Transformation is defmed as uptake of DNA into the host genome by homologous 
recombination of free DNA released into the environment by other bacterial cells. 
Transformation is the molecular basis of penicillin resistance in Neisseria [Spratt et ai, 
1994]. Penicillin-resistance penumococci produce altered penicillin binding proteins 
(PBSs) that have low affinity binding of penicillin. Nucleotide sequence analysis of the 
genes encoding these altered PBSs indicates that they are mosaics in which blocks of 
foreign DNA from a closely related species of streptococcus have been imported and 
incorporated into the resident PEP gene. 
(e) Conjugation is phenomenon of direct gene transfer through cell to cell contact by sex 
pilus or bridge. This complex and fascinating mechanism for spread of antibiotics 
resistance is extremely important because multiple resistance genes can be transferred in 
a single event. The transferable genetic material consists of two different sets of plasmid 
encoded genes that may be on the same or different plasmids. One set encodes the actual 
resistance; the second encodes genes necessary for the bacterial conjugation process. 
Conjugative plasmids tend to be rather large (>50 Kb). The combine element of plasmid 
DNA rolling-circle replication (only a single strand is transferred, and it replicates in the 
host) with a type of IV bacterial secretion system. Plasmid transfer requires an origin of 
transfer demarcating the site within the plasmid where transfer will occur, DNA 
replicating enzymes, and coupling proteins that direct the DNA across two cell 
membranes on its way from the host into the recipient. Genes encoding the resistance 
determinants may be located transposons. 
Conjugation with genetic exchange between nonpathogenic and pathogenic 
microorganisms probably occurs in the gastro intestinal (GI) tract of human beings and 
animals. The efficiency of transfer is low; however, antibiotics can exert a powerful 
selective pressure to allow emergence of restraint strain. Genetic transfer by conjugation 
is common among gram negative bacilli, and resistance is conferred on susceptible cell as 
a single event. Enterococci also contain a broad range of conjugative plasmid that are 
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involved in the transfer and spread of resistance genes among gram positive organism. 
Vacomycin resistance in Enterococci is mediated by a conjugative plasmid [Arthur and 
Courvalin, 1993; Murray et al, 20000]. Vancomycin resistance in S. aureus is due to 
conjugative transfer of vanA-type vancomycin resistance genes encodes on a transposon 
fix»m Enterococcus fecalis donor into methicillini-resistant strain of S. aureus with 
subsequent integration of the transposon into a resident staphylococcal conjugative 
plasmid. 
(f) Plasmids, a double stranded circular or linear DNA molecule capable of autonomous 
replication, are usually found in prokaryotes, although they exist in some groups of 
primitive eukaryotes as yeast, fungi and cellular slime moulds [Rush et al., 1985]. They 
are not organisms as they thought to be extra-chromosomal, accessory DNA elements 
[Reanney et al., 1976, Campbell et al., 1981]. Normally, Plasmids do not possess such 
genes that are essential for growth of their host in normal condition. Natural plasmids are 
able for their autonomous replication, controlling the copy-number and ensuring stable 
inheritance during cell division and many of them, through the conjugation process, can 
promote their horizontal transfer among bacteria of different genera and kingdoms. 
Extensive researches have been done to find out the role of plasmid in bacterial genome 
[Thomas et al., 2005]. Plasmids carry genes that confer a selectable phenotypic character 
under specific niche conditions. Antimicrobial resistance is best example of phenotypic 
advantage of plasmid [Lenski et al, 1998]. Resistance genes on plasmids give immediate 
offer to their host under antimicrobial therapy. Though, the real advantage of the plasmid 
location of resistance genes is not well established: transfer of plasmid-located resistance 
genes to the bacterial chromosome may disfavor the plasmid maintenance. Advantage of 
plasmid location for selectable genes may be hypothesized in the relative higher copy 
number of plasmids by increasing the gene dosage. But there are numerous other factors 
influencing the chromosome/plasmid harmony and evolution. Plasmids must be thought a 
selfish molecule that is autonomous in nature and encode extra genetic information, 
establish the complex relationships with Ae recipient host and play multiple roles in the 
bacterial population. Antimicrobial resistance arises from a complex multi-factorial 
process supported by panoply of mobile genetic elements that contain and transfer 
resistance determinants. Resistance genes located on plasmids move fi-om one bacterium 
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to another, conferring phenotypic characteristics. Several resistance plasmids have been 
identified and described to carry virulence factors, such as bacteriocins, siderophores, 
cytotoxins, or adhesion factors [Martinez et al, 2002] and virulence plasmids have been 
described to carry resistance genes [Guerra et al, 2002, Villa et al, 2005, Herrero et al, 
2006]. For plasmid carrying virulence and resistance linked determinants, an infective 
population will be selected for antimicrobial resistance, and antimicrobial resistance 
pressure will select the virulence traits. However, once those determinants have been 
selected in the bacterial host, they can evolve further and eventually be transferred to 
other bacterial population. The acquisition of antimicrobial resistance genes on virulence 
plasmids could represent a novel tool in bacterial evolution, implementing adaptive 
strategies to explore and colonize novel hosts and environments [Martinez et al, 2002]. 
Plasmid can code for more than one ^-lactamase in addition to their expression of 
chromosomal enzyme. Due to carriage of plasmids and promiscuous exchange of such 
material between bacteria, these resistance genes have spread widely and are also subject 
to mutations [Lee, Yuen & Kumana., 2001]. Plasmid mediated ^-lactamases were first 
recognized in Gram-negative bacteria in the early 1960s, shortly after the introduction of 
ampicillin [Livermore et al, 1993]. Plasmid-mediated resistance to p-lactam antibiotics 
in E. coli is of major concern in hospitals. A widespread resistance of £. coll to ampicillin 
and co-trimoxazole has been reported in South Africa [Klugman et al, 1993]. It has been 
reported that mortality and morbidity in prolonged hospitalization are twice as high in 
patients infected with antibiotic-resistant strains than with susceptible strains [Pitout et 
al, 1997; Silvae/a/., 1999; Lautenbach e/a/., 2001]. 
1.2.4 Multidrug resistance (MDR) in bacteria 
Multi-drug resistant organisms may be defined as bacteria with simultaneous resistance 
to three or more different classes of antibiotics [Guyot et al, 1999]. The rise in multi 
drug resistance organism attracted the world wide biomedical researchers. In a recent 
study in North America, it was foimd that more than 55% E.coU of fluoroquinolone 
resistant uropathogens were additionally resistant to ampicillin as well as trimethoprim-
sulfamethoxazole (TMP/SMX) [Zhanel, Unpublished data]. And it was also observed that 
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drug resistance cases were more common in those patients who had history of prolonged 
usage of antibiotic. Multi drugs resistant organism causes a higher degree of treatment 
failure and morbidity associated with infection [Gupta & Stamm., 2002; Sobel & Kaye., 
2004]. 
U P-Lactamases 
13.1 p-Lactamase: Definition, characterbtics and classification 
P-lactamases are categorized on the basis of similarity in amino acid sequence (Ambler 
classes A through D) or on substrate and inhibitor profile (Bush-Jacoby-Medeiros Groups 
1 through 4) (Table 1.2) [Ambler et al, 1980; Bush et al, 1995; Huovinen et al, 1991; 
Jaurin et al, 1981; Ouellette et al, 1987]. They are globular proteins that 
characteristically have a-helices, p-pleated sheets, and share similar structural features. 
Bush Group 2 enzymes (Ambler Class A) known as penicillinases are susceptible to |3-
lactamases inhibitors. The TEM-1 and SHV-1 ^-lactamases, Group 2b, are the P-
lactamases usually found in K. pneumoniae and E. coli that confer resistance to 
penicillins (ampicillin and piperacillin) [Bush et al, 1995]. Bush Group 3 enzymes 
(Ambler Class B) are MBLs that use one of two zinc (Zn2+) atoms for inactivating 
penicillins and cephalosporins. In bacteria, MBLs are among the most resistant 
phenotypes encountered by clinicians and confer resistance to carbapenems, 
cephalosporins and penicillins. MBLs are inhibited by chelating agents (EDTA), but not 
by clavulanic acid or sulfones. The bla genes encoding MBLs are found on a variety of 
genetic elements (chromosome, plasmid, integrons, etc.) [Walsh et al, 2005]. IMP-type 
and VIM-type of P. aeruginosa possessing MBLs are most widespread and clinically 
unportant and around 20% of imipenem-resistant P. aeruginosa strains have been 
reported possessing a MBL. Bush Group 1 enzymes (Ambler class C) include the 
chromosomal ly encoded AmpC type P-lactamses nad has been observed in Citrobacter 
freundii, Enterobacter aerogenes and Enterobacter cloacae, Morganella morganii, P. 
aeruginosa and Serratia marcescens. 
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Table 1.2 ^-lactamase ciassiiication by Bush and Jacoby 
Ambl«r 
class 
C 
C 
A 
A 
A 
A 
A 
A 
A 
0 
D 
D 
A 
A 
B 
B 
Unkown 
Bushviacoby 
group 
1 
1e 
2a 
2b 
2be 
2br 
2ber 
2c 
2ce 
2d 
2(ie 
2df 
2e 
2f 
3a (B1) 
(82) 
3b (83) 
4 
Oistinctiva substrates 
Cephalosporins 
Cephalosporins 
Pencillins 
Pendllins, 
early cephalosporins 
Extended-spectrum 
cephalosporins, 
monobactams 
Penicillins 
Extended-spectrum 
cephalosporins, 
monobactams 
Caribencillin 
Carbendllin, cefepime 
Cloxacillin 
Extended-spectmm 
cephalosporins 
Carbapenems 
Extended-spectrum 
cephalosporins 
Caril>apenems 
Carisapenems 
Cart)apenems 
-
inhibited by 
CA/TZB 
-
-
+ 
+ 
+ 
+ 
+ 
V 
V 
V 
+ 
V 
" 
-
EDTA 
-
-
-
-
-
-
_ 
^ 
+ 
+ 
Representative enzymes 
AmpC, P99, ACT-1,CMY-2, F0X-1,MIR-1 
GC-1, CMY-37 
PCI 
TEM-1,TEM-2. 
SHV-1 
TEM-3, SHV-2, CTXMs.PER, VEB 
TEI^-30, SHV-10 
TEM-50 
PSE-1, CARB-3 
RTG4 
OXA-1.OXA-10 
0XA-11,0XA-15 
OXA-23,0XA-48 
CEPA 
KPC-2, IMI-1, SME-1 
IMP-1, VIM-1, IND-1, CcrA 
L1,CAU-1,G0B-1,FEZ-1 
CphA,S<h-1 
Mostly no ^  sequenced 
(V), Variable; (+), Yes; (-), No; CA, Clavulanic acid; TZB, Tazobactam 
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Penicillins, ^-lactamase inhibitors, cefoxitin, cefotetan, ceftazidime, ceftriaxone, and 
cefotaxime were observed to be resistant in bacteria having AmpC P-lactamases. 
However, aztreonam and cefepime are usually more active against bacteria possessing 
class C P-lactamases. Earlier, the encoding gene, ampC was thought to be located 
exclusively on chromosome but, now an increasing number of ampC genes have been 
identified on plasmids [Walther-Rasmussen et al, 2002], and mostly acquired by AmpC 
deficient pathogenic bacteria, which consequently are supplied with new and additional 
resistance phenotypes. Bush group 2f enzymes (Ambler class D), serine P-lactamases, are 
able to hydrolyze oxacillin and, hence knows as oxacillinases or OXA P-lactamases. 
Acinetobacter baumannii and P. aeruginosa represent the most structurally diverse and 
rapidly growing group of OXA P-lactamases [Brown et al, 2006; Walther-Rasmussen et 
al, 2006]. These P-lactamases due to OXA enzyme confer resistance to penicillins, 
cephalosporins, extended spectrum cephalosporins (OXA-type ESBLs) or carbapenems 
(OXA-type carbapenemases). OXA enzymes are inhibited by sodium chloride but found 
to be relatively resistant to clavulanic acid inactivation, [Naas et al, 1998; Poirel et al, 
2002]. 
13.2 p-Lactamases mediated resistance to p-lactam antibiotics 
TEM-1, TEM-2 and SHV-1 are widespread enzymes that are responsible for resistance to 
the narrow spectrum cephalosporins, cefamandole and cefoperazone and most of the 
penicillins. Word "TEM" is derived from Temoniera, name of patient, from whom 
resistant bacteria were isolated, whereas SHV is abbreviation of sulfhydryl variable that 
indicate the biochemical properties of this p-lactamase [Heritage et al, 1999]. In 
epidemiological study, it has been found that plasmid mediated enzymes TEM-1, TEM-2 
and SHV-1 most commonly encountered with TEM-1 predominant and responsible for 
90% ampicillin resistance in E. coli [Baker et al, 1999]. Amount of TEM and SHV 
enzymes indicates the degree of resistance and it can vary 150 fold among isolates, 
reflecting gene dosage and promoter efficiency [Reguera et al, 199; Heritage et al, 
1999]. Recognition and identification of these enzymes may be made on the basis of 
biochemical criteria (substrate profiles, kinetic properties and reaction with inhibitors), 
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physical properties (molecular size and isoelectric point), or by genetic criteria, such as 
inducibility and location of their genes on plasmids or on the chromosome [Philippon et 
al, 1989; Jacoby et al., 1994; Livermore & Williams, 1996]. P-lactamases can produce 
antibiotic resistance through multiple ways. In some bacteria as in E. coli (TEM-1 
producers), the ^-lactamases remain localised in the periplasmic space and can destroy 
antibiotic molecules when make their way through the outer membrane and as a resultant, 
high level of resistance occurs within a single bacterial cell [Medeiros et a/., 1984; Zhou 
et al., 1994]. Affinity for the antibiotic (Km), rate of hydrolysis (Vmax), and the amount 
of P-lactamase are among the most important factors that contribute to the level of 
antibiotic resistance mediated by a particular ^-lactamase in a population of bacteria. 
[Pitout et al, 998]. In eight decade of last century, extended spectrum cephalosporin 
resistance due to production of P-lactamases has been observed in Gram negative 
bacteria. And it was also observed that first extended spectrum ^-lactamases was derived 
from SHV-1 or TEM-1 p-lactamases after mutation. The genes encoding these mutants 
are present on mobile genetic elements, facilitating their spread in nosocomial pathogens 
[Heritage et al, 1999]. 
a. TEM-1 p-lactamases 
Most common plasmid encoded ^-lactamase, TEM-1, was first discovered in E.coli in 
1965 [Bryan & Godfrey, 1991; Ho et al, 1998], and has been observed spreading to 20-
60% of Enteriobacteriaceae isolates with varying frequency in species and location. Its 
expression is nothing but constitutive with variable concentration among strain. 
Ampicillin, amoxicillin and ticarcillin were found to be resistant to lesser concentration 
of TEM-1 while piperacillin, mezlocillin, cephalothin, cefamandole and cefoperazone 
were observed to be resistant to higher concentration of TEM [Livermore et al, 1993]. 
b. SHV-1 p-Iactamases 
SHV-1 is classified in the Bush group 2b enzymes [Sanders & Sanders., 1992] and is 
encoded by SHV-1 gene, commonly encountered in clinical isolates on self-transmissible 
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plasmids. It was first described as a chromosomally encoded ^-lactamase in Klebsiella 
[Heritage et al, 1999]. It is a narrow spectrum ^-lactamase and has activity against 
penicillin. Production and concentration of enzyme amongst strains is variable more than 
one hundred fold as it depends on the number of plasmid copies per organism, the degree 
of gene amplification and the efficiency of the promoter and [Jacoby & Carreras, 1990; 
Abdel-Rahman & Keams, 1998; Petrosino et al, 1998]. 
133 Extended spectrum P-lactamases (ESBLs) 
Extended spectrum ^-lactamases (ESBLs) are globular proteins composed of alpha-
helices and beta-pleated sheets [Knox et al, 1995]. ^-lactamases hydrolyze extended-
spectrum cephalosporins with an oxyimino side chain, e.g., CTX-M 
[http://en.wikipedia.org / wiki / Beta-Lactamase]. Plasmid encoded ^lactamases; TEM-1, 
TEM-2, and SHV-1 in Enterobacteriaceae family confer resistance to penicillin but not 
to expanded spectrum cephalosporins [Harbak et al, 2007]. ESBLs are derived from 
genes for TEM-1, TEM-2, or SHV-1 by mutations that alter the amino acid composition 
around the active site of these ^-lactamases. They are classified in group 2be in Bush-
Medeiros-Jacob system and class A in Ambler system. It was observed that point 
mutation in SHV and TEM P-Iactamases which cause single amino acid substitution (Asp 
104- Lys, Argl64-Ser, Argl64-His, Aspl79-Asn, Gly238-Ser and GIu240- Lys) are 
responsible for the resistance[PhiIippon & Jacoby, 1989 & Medeiros,1991]. Hence these 
enzymes are potent weapon of bacteria as they extend the susceptibility of p-lactam 
antibiotics to hydrolysis. [Harbak et al, 2007; http://en.wikipedia.org/wiki/ Beta-
lactamase]. ESBLs are usually capable of hydrolyzing penicillins (e.g. ampicillin and 
piperacillin), cephalosporin of first, second, third and fourth generation and the 
monobactam azotreonam but not to cephamycins or carbapenems [Amber et al, 1991]. 
The distinctive property of ESBLs (e.g. members of TEM and SHV families) of being 
exploited by P-lactamase inhibitors such as clavulanic acid, tazobactam or sulbactam, is 
duly exploited in double-disk synergy test meant for ESBL detection [Rossolini et al, 
2006]. The ESBLs are frequently plasmid encoded and plasmids responsible for ESBL 
production frequently carry genes encoding resistance to other drug classes (for example. 
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aminoglycosides) [Bradford et al, 2001]. Therefore, antibiotic options in the treatment of 
ESBL-producing organisms are extremely limited. ESBL producing organisms may 
appear susceptible to some extended-spectrum cephalosporins. However, treatments with 
such antibiotics have been associated with high failure rates 
[http://en.wikipedia.org/wiki/Beta-Lactamase]. Carbapenems are the treatment of choice 
for serious infections due to ESBL producing organisms, yet carbapenem resistant 
isolates have recently been reported [Rossolini et al, 2006; Bradford et al, 2001]. 
13.4 CTX-M p-lactamases 
CTX-M is a recently described family of the extended-spectrum P-lactamases 
[Tzouvelekis et al, 2000] and they are now considered the most prevalence ESBLs 
worldwide [Livermore et al, 2007]. These enzymes show potent hydrolytic activity 
against cefotaxime and hence they are called as CTX-M [Bonnet et al, 2004]. Bush et 
al, (1993) has reported that they hydrolyze cephalothin better than benzylpenicillin and 
preferentially hydrolyze cefotaxime over ceftazidime. CTX-M inhibition is observed to a 
greater extent in Tazobactam than in sulbactam or clavulanate [Bush et al, 1993]. They 
generally found as plasmid acquisition of P-lactamases genes on chromosome of 
Kluyvera species. [Humeniuk et al, 2002]. CTX-M type p-lactamases have 40% or less 
identity with TEM and SHV type ESBLs CTX-M p-lactamases. The number of CTX-M 
type P-lactamases, which is most frequent type of ESBLs worldwide, is rapidly 
expanding and more than 40 CTX-M variants are identified in K.penumonia, E.coli, 
typhoidal and non typhoida! Salmonella, Shigella, Citrohacter freund, Enterobacter spp., 
and Serratia marcescens [Walther-Rasmussen & Hoiby, 2004; Tzouvelekis et al, 2000; 
Bradford et al, 1998]. CTX-M enzymes can be sub classified by amino acid sequence 
similarities and on the basis of phylogenetic studies; acquired CTX-M enzymes may be 
divided in another five major groups. 
Selective remodeling of active sites to accommodate the bulky Rl side chain of extended 
spectrum cephalosporins is one of the most important observations as revealed in study of 
the atomic structures of class A ESBLs [Knox et al, 1995]. Amino acid residues Asnl04, 
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Asnl32, Ser237, and Asp240 have been identified as the key factors behind the substrate 
specificity of the CTX-M ^lactamases by several studies that used comparative sequence 
analyses, modeling, and mutagenesis techniques [Bauemfeind et al., 1996]. Ser 237 has 
been observed to be involved in the extension of the substrate specificities of TEM and 
SHV ESBLs to cefotaxime [Knox et al, 1995]. The Ser237Ala substitution in the CTX-
M-4 enzyme induces a decrease both in relative hydrolytic activity against cefotaxime 
and in susceptibility to inhibition by clavuianate [Gazouli et al, 1998]. The acyl 
intermediate structure of Toho-1 in complex with cefotaxime shows a rotation of the 
Ser237 side chain, which prevents steric clashes with the methoxyimino group of 
cefotaxime and which allows the formation of a hydrogen bond with the carboxylate 
group of cefotaxime [Shimamura et al, 2002]. It has been suggested that this interaction 
assists in bringing the carbonyl group of the p-lactam ring of cephalosporins to the 
optima] position in the oxyanion hole for acylation [Shimamura et al, 2002]. The 
relatively low penicillinase activities of CTX-M enzymes may be caused by Van der 
Waals contact between residue Ser237 and the methyl group of the thiazolidine ring. 
Asnl04, Asnl32, Ser237, and Asp240 residues establish hydrogen bonds with the amide 
and aminothiazole groups of the acyl-amide-cefotaxime chain. This unusual acyl 
intermediate of CTX-M enzymes in complex with cefotaxime may therefore be involved 
in the activities of the oxyimino-cephalosporinases by fixing cefotaxime tightly in the 
binding site [Shimamura et al, 2002]. The structure of Toho-1 revealed that the omega 
loop (amino acid positions 161-179) has fewer hydrogen bond interactions with the P3 
strand in the vicinities of Asnl70 and Asp240 than the restricted-spectrum p-lactamase of 
Bacillus licheniformis, the enzyme most closely related to Toho-1 at the structural level. 
No hydrogen bond has been observed between the Phel60 residue and ThrlSl and 
Asp 157 residues, which both connect the N and C termini of the omega loop in restricted-
spectrum P-lactamases [Ibuka et al, 1999]. These structural features may increase the 
flexibility of the omega loop. The structures of acyl intermediates of the Toho-1 enzyme 
show a shift of the omega loop to helix H5 [Shimamura et al, 2002] as a result of a 
complex structural rearrangement in the hydrophobic core in the vicinity of the omega 
loop (the residues involved in the rearrangement are Cys69, Ser72, Metl35, Phel60, and 
Thrl65). This shift narrows the binding site, but the steric contacts of the Prol67 and 
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Asnl70 residues with the aminothiazole ring of cefotaxime are avoided. Mutants with 
point mutations in common CTX-M enzymes exhibiting improved catalytic efficiencies 
against ceftazidime have been observed [Knox et al, 1995]. The change in activities of 
CTX-Ms leading to the evolution of more variants may be due to point mutations present 
either inside or outside of the active site omega loop (amino acid positions 161 to 179) 
[Sturenburg et al, 2004]. For example the P167T mutation differentiates CTX-M-23 
from CTX-M-1, CTX-M-3 and CTX-M-15. However the CTX-Ms, having identical 
residues present in the omega loop may still have some difference in their enzymatic 
activities due to mutations present outside the omega loop. The CTX-M-15, CTX-M-16, 
and CTX-M-27 enzymes harbor the Asp240Gly substitution. The presence of Lys and 
Arg residues at position 240 are known to increase the enzymatic activities of the TEM 
and SHV types ESBLs against ceftazidime [Knox et a/., 1995]. The Lys and Arg residues 
are positively charged and can form an electrostatic bond with the carboxylic acid group 
on oxyimino substituents of ceftazidime [Huletsky et al, 1993; Cantu et al, 1996]. 
Neutral residue Gly240 is not able to form electrostatic interactions with p-lactams but 
could favor the accommodation of the oxyimino-ceftazidime side chain [Bonnet et al, 
2001; Bonnet et al, 2003]. 
1.3.5 OXA p l^actamases 
The OXA ^lactamases belong to class D (2d) in Ambler classification [Ambler, Coulson 
et al 1991], mainly occur in Acinetobacter and Pseudomonas species. The OXA P-
lactamases is responsible to attack the oxyimino-cephalosporins. They also have a high 
hydrolytic activity against oxacillin, methicillin and cloxacillin more than 
benzylpenicillin and inhibited less efficiently by clavulanate but efficiently with NaCl 
[Heritier et al, 2005; Poirel and Nordmann, 2006; Walther-Rasmussen and Hoiby, 2006]. 
At present, more than 180 different variants of OXA enzymes have been identified on the 
protein level (http://www.lahey.org/studies/). Most of the genes encoding class D 
oxacillinases have commonly been found on plasmids incorporated as gene cassettes in 
integrons. For example, OXA-58 has been reported to confer resistance to imipenem 
through plasmid mediated gene transfer in A. batimannii [Zarrilli et al, 2008]. Several 
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chromosomal encoded oxacillinases have been reported [Heritier, Poirel et al., 2005; 
Walther- Rasmussen & Hoiby., 2006]. Most OXA-type ^-lactamases do not hydrolyse 
the extended-spectrum cephalosporins and hence they are not regarded as ESBLs. OXA-
11 a variant of OXA-10 (previously known as PSE-2), the first extended-spectrum from 
P. aeruginosa 29 ABD is identified in October 1991 from blood cultures of a bum patient 
in Turicey [Hall, Livermore et al., 1993]. Substitutions of an asparagine for serine at 
position 73, or an aspartate for glycine at position 157 are probably required for the 
ESBL phenotype [Bradford et al, 2001]. Most OXA-type ESBLs derive from OXA-10 
(OXA-U, OXA-13, OXA- 14, OXA-16, OXA-17 OXA-19 and OXA-28), to a lesser 
extent from OXA-2 (OXA-15 and OXA-32), and others unrelated to any recognized 
broad spectrum OXA enzymes (OXA-18 and OXA-45) [Naas et al., 2008]. In 1993, 
Paton et. al identified and described the first OXA ^ -lactamase ARI-1 (for "Acinetobacter 
resistant to imipenem") as OXA-23 with carbapenemase activity from a strain isolated in 
1985 from a patient in the Royal Infirmary of Edinburgh, Scotland. Carbapenems 
hydrolysis by the class D oxacillinase in A. baumannii was classified into four subgroups 
of eight clusters and they have been designated OXA-23-like; OXA-40-like; OXA-51-
like and OXA-58-like [Brown & Amyes., 2006], whereas Walther-Rasmussen and Hoiby 
(2006) subclassified carbapenem-hydrolysing OXA enzymes into eight distinct branches 
or subgroups including OXA-23, OXA-24, OXA-48, OXA-50, OXA-51, OXA-55, OXA-
58 and OXA-60. OXA-62 is another subgroup carbapenem-hydrolyzing oxacillinase 
which was identified in Pandoraea pnomenusa from cystic fibrosis patients [Schneider et 
al., 2006]. Poirel et al (2005) has observed OXA-51-like enzymes in all tested A. 
baumannii strains. 
1.4 Neonatal infections 
Immature immune system, particularly of preterm baby is one of the most important 
causes for neonatal infection [Fanos et al., 2007]. Because antibodies which help and 
protect the mothers fit)m infections do not cross through the placenta to the fetus until 
approximately 30 weeks of gestation and also they do not reach up to optimum level at 
birth time and hence affects the protection provided. Neonatal Infection may be classified 
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into three main groups: intrauterine, intrapartum, and postnatal infections. These three 
groups have several factors that increase the risk of neonatal infection. 
Intrauterine infections occur when pathogenic organisms cross the placenta into the fetal 
circulatory system. The organisms, such as cytomegalovirus (CMV), can reside in the 
amniotic fluid. Other organisms ascend fix)m the vaginal track, infecting the membranes 
and causing them to rupture. This rupture of membranes can lead to infections of the 
respiratory and gastrointestinal tract of a newborn. Therefore, poor prenatal care, poor 
nutrition, recurrent abortions, and substance abuse are identified as most important risk 
factors for intra uterine neonatal infection. Factors which are responsible for neonatal 
infection during the birth process or intra-partum period include: prolonged rupture of 
membranes (>12 to 18 hours), urinary tract infections, preterm labor, prolonged or 
difficuk labor, maternal fever and maternal infections. Most infections during delivery of 
fetus are related to the infant coming into unavoidable contact with an infected birth 
canal. The birth canal can host bacteria that an infant's immune system cannot defend 
against infections in the postnatal period which are more common in those infants who 
require foreign objects to be introduced into their systems. Items like endo-tracheal tubes 
or indwelling catheters increase the neonatal infection. This is much commonly observed 
during resuscitation, or as a resuh of a nosocomial infection due to improper hand 
washing. But, the single most important risk factor for infection in the neonate is 
prematurity [Seo et al, 1992]. However, factors that increase the infant's chance of 
becoming sick include: low birth weight (Infants weighing less than lOOOg are at the 
highest risk for infections), prematurity, birth asphyxia, meconium staining, and 
resuscitation. Premature neonates are generally supposed to have higher risk of 
developing infection due to immature immune system, thinner skin, frequent need for 
insertion of foreign objects and use of prolonged ventilator in high risk of neonates for 
chronic lung disease [Elster et al, 2009]. Some life saving drugs like corticosteroids 
which are essential to help and treat illness of neonates may leave the infant at an 
increased risk of infection. Pathogen found in cerebrospinal fluid (CSF), urine, and 
bacterial blood cultures are the main source that conflrms infection in a neonate. Some 
other pathological condition like hypoglycemia, hyperglycemia, metabolic acidosis, 
thrombocytopenia, or hyperbilirubinemia may be taken as another source and may be 
29 
Saeedut Zafar AU, 2012 \ Chapter-1 
checked in an infant suspected of sepsis. The blood culture and complete blood count 
(CBC) is the most important tool to recognize the causative organism and infection. 
Increased or decreased white blood count (WBC), low platelet count and a high I:T ratio 
indicate the presence of infection [Aulia et al, 2003]. I:T ratio is used an index to show 
the percentage of immature white blood cells to total white blood cells. Greater I:T ratio, 
more than 0.2, indicates a "left shift" that means more inunature neutrophils than mature 
neutrophils are circulating in the bloodstream due to acute infective condition. And when 
the severity of infection declines neutrophils come back to its normal level, a "shift to the 
right" occurs, indicating that everything is in its normal limit. 
1.4.1 Klebsiella pneumoniae and neonatal infections 
K. pneumoniae, an opportunistic pathogens mainly in immunocompromised and in other 
high risk patient groups, is responsible for community acquired infections such as 
primary lobar pneumonia and 8-13% of cases of UTIs. [Murray et at., 1998]. Nosocomial 
infections and infections of wound or soft tissues are also known to be caused by this 
opportunistic pathogen. [Vaara & Vaara, 1983; Murray et al, 1998]. Patients with central 
venous and urinary tract catheters, patients on mechanical ventilation and people with 
compromised pulmonary ftinction are also at risk of being infected with K. pneumoniae 
[Jarlier et al, 1988; Weiner et al, 1999; Rebuck et al, 2000; Lautenbach et al, 2001]. 
Presence of cell wall receptor, K antigen, production of long chain -O- antigen and large 
plasmid are the most important factors which contribute to the virulence of K. 
pneumoniae as cell wall receptors enable the organism to attach to host cells and protect 
the bacteria fix>m phagocytosis and intracellular killing by polymorph nuclear leukocytes 
where as K antigen, an extensive polysaccharide capsule, protects the bacterial cell from 
phagocytosis and directly suppresses the immune response [Mims et al, 1993; Hooton et 
al, 2000]. Production of long chain-O-antigen polysaccharide in the endotoxin of the 
outer membrane may contribute to resistance by inhibiting complement-mediated serum 
killing. And large size of plasmid (>200 kb) encodes aerobactin (a protein involved in 
iron acquisition and regulation of the mucoid phenotype) and thus becomes a reason for 
virulence ofK. Penumoniae. 
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1.4.2 E. coli and neonatal infections 
It is worldwide established fact that E. coli is the most common cause of gram negative 
neonatal infections. Mother's genital tract is thought to be primary source of colonization 
in neonates. The pathogen has a wide spectrum pathological manifestation in human 
being and can cause respiratory distress, cardiovascular collq>se, meningitis, multi-organ 
failure, and even death. Gentamicin and amikacin are drugs of choice for treatment of 
E.coli mediated infective conditions in neonatal intensive care unit. 
1.5 Diabetic foot ulcer/infection 
According to World Health Organization diabetic foot is defined as 'the foot of a diabetic 
patient that has the potential risk of pathologic consequences, including infection, 
ulceration, and destruction of deep tissues associated with neurologic abnormalities , 
various degrees of peripheral arterial disease, and metabolic complications of diabetes in 
the lower limb' [Frykberg et al, 2006]. In India, diabetes is the most alarming health 
problem and is expected to increase to 57 million populations by 2025 [Abdul et al, 
1999]. Diabetic Foot ulcer is the most common single precursor to amputation and has 
been identified as a component in 85% of lower- extremity amputations [Margolis et al., 
2005]. It has also been reported that 15% of diabetic patients would develop a foot ulcer 
during the course of their disease [Boulton et a/., 2004]. Neuropathy, and impaired blood 
supply in combination with deformities of the feet and the resulting increased pressures 
on areas of the sole are the most important pathophysiological factors. History of 
previous foot ulcers and amputation, inadequate footwear, a lack of (or low-quality) 
podiatry care, poor diabetes management, long duration of diabetes, chronic renal 
disease, poor visual acuity, psychological factors and behavioral factors, smoking, old 
age and low social status are also important contributing factors. 
Diabetic foot infection is a broader term that includes paronychia, cellulitis, myositis, 
abscesses, necrotizing fasciitis, septic arthritis, tendonitis, and osteomyelitis in 
association of diabetes mellitus. But the most common form of diabetic foot infection is 
diabetic foot ulcer which mainly results tcom neuropathy, ischemia and other complex 
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mechanism [Lipsky et al., 2004]. Because, diabetic foot ulcer that breaches the protective 
layer of skin and exposes the underlying soft tissue, provides a better media for bacterial 
colonization. Due to this bacterial colonization and ischemic condition, the wound may 
fiirther progress to become actively infected and involve deeper tissue. However, several 
other pathophysiological factors increase the risk and severity of foot infections 
[Schubert & Heesemann., 1995]. But, abnormal cellular, inflammatory and 
immunological response to bacterial toxins in diabetes causes increased vulnerability to 
infection and delayed wound healing process that ultimately complicate the ulceration 
[Yan et a/., 2003; Delamaire et al., 1997]. Increased Blood glucose level also increases 
the rate of infection in diabetic foot ulcer. Arteriovenous communication and impaired 
intermediary tissue metabolism in diabetic patients also predispose them to infection and 
then compound the problem by potentiating infection once a pathogen has been 
introduced. 
Etiology Among the various causative organism isolated from infected foot ulcer, 
staphylococcus has been predominantly observed \X\x et al, 2007; Yates et al., 2009]. 
Pseudomonas aeruginosa [Martinez-G6mez et al., 2009], E. coli [Varaiya et al., 2008], 
Klebsiella species [Goldstein et al., 2008], Enterococcus species [Martinez-G6mez et al., 
2009], and Proteus species [Raja et al., 2007] have also been observed and reported in 
various diabetic foot ulcer cases. But the classical signs and symptoms of these pathogen 
mediated infection remain hidden in two third patients of mfective diabetic foot ulcer 
probably due to neuropathy, alteration in microcirculation and leukocyte abnormalities. 
Extensive foot infection, and increased blood glucose level are remain the sole presenting 
sign. 
Wagner Classification System Various classification systems are made to define and 
determine the severity of diabetic foot ulcer. Most common and widely used 
classification system is the Wagner System [Wagner et al., 1981]. This system is 
basically anatomical with gradations of superficial ulcer, deep ulcer, abscess osteitis, 
gangrene of the fore foot, and gangrene of the entire foot. Only grade 3 addresses the 
problem of mfection. hi this system, foot lesions are divided into different grades starting 
from grade 0 to grade 5. Grade 0 includes high risk foot but no active lesion and grade 5 
includes gangrene of entire foot. 
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Diabetic foot infection and antibiotic regime As a general rule, control of infection is 
the first priority in the management of diabetic foot problem. Even minor infected foot 
lesions in the diabetics should always be taken seriously and treated early with suitable 
antibiotics. Selection of the antibiotic regimen mainly depends on the route of drug 
administration, the spectrum of microorganisms to be covered, the specific drugs to 
administer, and the duration of treatment. For severe infections and for more-extensive, 
chronic moderate infections, it is safest to commence therapy with broad-spectrum 
agents. These should have activity against gram-positive cocci (including MRSA in 
locations where this pathogen is common), as well as gram-negative and obligate 
anaerobic organisms. Clinical trials suggest that fluoroquinolones, cephalosporins, P-
lactam inhibitor penicillins, and carbapenems are effective. These suggested agents are 
derived fi"om available published clinical trials and are not meant to be inclusive of all 
potentially reasonable regimens. Similar agents could be used, depending on various 
clinical, microbiological, epidemiological, and financial considerations such as imipenem 
which was reported equally effective against Gram-positive and negative diabetic foot 
isolates and vancomycin against gram-positive isolates [Raja et a/., 2007]. 
1.6 Molecular ciiaracterization/Typing of clinical isolates 
Different methods are being used to type bacterial isolates, which include restriction 
endonuclease assay (REA) [Savio et al, 1994; Brown & Levett, 1997], pulsed field gel 
electrophoresis (PFGE) [Herrmann et a/., 1991; Herrmann et al, 1992], restriction 
fi:agment length polymorphism (RFLP) [Zuemer et al, 1993], arbitrarily primed PCR 
[Perolat et al, 1994], Variable Number of Tandem Repeats (VNTR) analysis [Majed et 
al, 2005] and fluorescent amplified fi-agment length polymorphism (FAFLP) 
[Vijayachari et al, 2004]. These methods fffe considered to be valuable tools for 
distinguishing the bacterial strains or clones and as an integral part of clinical as well as 
microbiological research. These methods are highly discriminatory and have added 
greatly to our knowledge of the epidemiology of many pathogenic bacteria in outbreak 
settings, such as methicillin-resistant Staphylococcm aureus (MRSA) [de Lencastre et 
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al, 1996; Roberts et al, 1998; Macfarlane et a/., 1999] and vancomycin-resistant 
enterococcal infections in hospitals [ Morrison et al, 1999] and outbreaks of E. coli 
0157:H7 food poisoning [Gouveia et al., 1998; Besser et al, 1999] and meningococcal 
meningitis [Jelfs et al, 1998] within the community. 
1.6.1 Multilocus sequence typing (MLST): 
MLST, a novel molecular typing method based on the principles of multilocus enzyme 
electrophoresis (MLEE) [Selander et al, 1986] has been developed and used in study of 
many bacterial species like Neisseria meningitides [Maiden et al, 1998], Streptococcus 
pneumoniae [Enright & Spratt., 1998], Streptococcus pyogenes [Enright et al, 2001], 
Staphylococcus aureus [ Enright et al, 2000], Yersinia species [Kotetishvili et al, 2005.], 
Campylobacter jejuni [Dingle et al, 2001] and Helicobacter pylori [Devi et al, 2006]. 
It is a simple nucleotide sequence-based PCR technique for characterizing the genetic 
relationships among bacterial isolates, which makes use of automated DNA sequencers to 
assign and characterize the alleles present in each locus. Nucleotide sequencing explores 
all of the variation at a locus. Number of alleles assigned per locus is much higher than in 
MLEE and the sequences of 450-500-bp internal fragments of only seven housekeeping 
genes are determined for each isolate. This length of DNA fragment can be sequenced 
accurately on both strands using a single pair of primers and, in most bacterial pathogens; 
it provides sufficient variation to identify many different alleles within the population. 
Different sequences, for each gene, are assigned as alleles and the alleles at the seven loci 
provide an allelic profile, which unambiguously shows the sequence type (ST) of each 
isolate. Sequences, if are different at even a single nucleotide, are assigned as different 
alleles and no consideration will be given to the number of nucleotide differences 
between alleles, as it cannot be distinguished whether differences at multiple nucleotide 
sites are a result of multiple point mutations or a single recombinational exchange. Allele 
at each of the seven loci provides the ability to differentiate billions of different allelic 
profiles. Strain with the frequent allele at each locus occur by chance approximately once 
in 10 000 isolates. It is rare that two unrelated isolates will have the same allelic profile 
[Spratt e/a/., 1999]. 
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MLST is highly discriminatory generating unambiguous sequence data in a low to high-
throughput scale, and the accumulation of nucleotide changes in housekeeping genes is a 
relatively slow process and stable for longer duration [Enright et ai, 1999]. Hence, the 
allelic profile of a bacterial isolate may be used for global epidemiology as highly robust 
markers of ancient and modem ancestry. A dendrogram, to find out the relatedness of 
isolates, may be prepared using the matrix of pair-wise differences between their allelic 
profiles. The dendrogram is display of isolates having identical or very similar allelic 
profiles and that can be assimied to be derived fi-om a common ancestor. Difference at 
more than three loci out of seven loci in bacterial isolates cannot provide any relationship 
among tiiem and should not be considered for the inference of their phylogeny [Spratt et 
ai, 1999; Spratt & Maiden., 1999]. It also provides computerized data that allow multi-
user international databases available. The sequencing of multiple loci provides a balance 
between technical feasibility and resolution. Recent studies showed that MLST is more 
appropriate for strain phylogeny and large scale epidemiology. Analysis of nosocomial 
isolates showed that MLST can discriminate among epidemiologically unrelated isolates 
[Diancourt etal, 2005; YmonXetal, 2008]. 
1.6.2 Replicoa typing/Incompatibility 
As mentioned above, plasmids are extra-chromosomal circular fi^gments of DNA and 
replicate autonomously in a host cell. They are usually seen in all bacterial species in 
variable size ranging fi-om a few to more than several hundred kilobase pairs. [Waters et 
al, 1999]. Plasmids are thou^t to contain a backbone of core genes tiiat remains 
relatively stable for long evolutionary periods and simultaneously increases the genetic 
diversity of bacteria by acquisition and loss of genes as they horizontally exchange 
among bacterial species by conjugation or mobilization [Francia et al., 2004]. Beside the 
core genes that are responsible for initiation and control of replication, some accessory 
genes that may be usefijl to their bactoial host such as antimicrobial resistance or 
virulence genes, are also found here [Amabile- Cuevas and Chicurel, 1992; Bergstrom et 
al, 2000; Thomas et a/., 1973]. The identification and characterization of the core genes 
of a plasmid species has a special relevance in the study of its epidemiology and modes 
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of transmission that will explore the main routes of that genes, for example antibiotic 
resistance genes, use to travel firom environmental reservoirs to hummi pathogens. 
Because, worldwide dissemination of plasmid mediated muhiple antibiotics resistance 
and virulence traits is an increasing threat for the treatment of many bacterial diseases. To 
follow the dissemination of virulence and antibiotic resistance genes, identification and 
categorization of the causative plasmids and following of their path from reservoirs to 
pathogens is necessary. Novick (1987) has developed the incompatibility grouping for 
classification and categorization of plasmid. He introduced, by conjugation or 
transformation, a plasmid of an "unknown" Inc group into a strain carrying a plasmid of a 
known Inc group. The incoming plasmid of unknown hic group will be assigned to its 
same Inc group if the resident plasmid is eliminated in progeny [Datta & Hedges., 1971]. 
So, on the basis of diis expression, plasmids with the same replication control and 
plasmids with different replication controls are termed as incompatible and compatible 
plasmid and two plasmids of same Inc group cannot be propagated in the same cell line 
[Datta and Hughes, 1983; Couturier er a/., 1988]. 
Incompatibility method has been frequently used to classify and to identify the plasmid, 
to trace the diffusion of plasmids conferring antimicrobial resistance, and also to follow 
the evolution and spread of emerging plasmids [Anderson et al., 1977]. An another 
method based on hybridization with 19 DNA probes that recognize different basic 
replicons, for the identification of the major rqjlicons of plasmids circulating among the 
Enterohacteriaceae^ was developed by Couturier et al (1988). But this conjugation and 
hybridization based methodologies cannot be easily applied to a large number of strains 
and their application has been limited by the laborious and time consuming work. For 
classification and categorization of plasmids, now a days PCR-based replicon typing is 
the method of choice in clinically relevant bacteria. It was observed that the PCR-based 
method can be applied directly on collections of strains to track the spread of plasmids 
conferring drug resistance, monitor the circulation of plasmids within strains from 
different environments and to follow the horizontal transmission of antimicrobial 
resistance genes among the Enterobacteriaceae [Pezzella et al, 2004]. 
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1.7 Objectives of the study 
In the light of above background, present study was initiated with the following 
objectives: 
1. To find the prevalence and susceptibility pattern of plasmid mediated ESBL-
producing E. coli, Klebsiella pneumoniae and pseudomonas species in the 
Intensive care unit (ICU) of Aligaib, hospital, India. 
2. To identify the risk factors associated with the transmission of WACTX-M, WOTEM 
and WflsHV among the ESBL-producing K. pneumoniae strains of the NICU. 
3. To characterize the mode of transmission of blacrx-u, WATEM and blasttv among 
the ESBL-producing K. pneumoniae strains of the NICU. 
4. To understand the Molecular mechanism of inhibitor resistant ESBL producing K. 
pneumonia isolated from NICU. 
5. To screen the metallo-P-lactamase (MBL) producing isolates in diabetic foot ulcer 
patients of endocrinology ward and ICU at the JNM College and hospital, 
Aligarh. 
37 

Saeedut Zafar Ali, 2012 Chapter-2 
2.1 Materials 
Materials used during the study are given below: 
2.1.1 Chemicals, reagents and 
Agarose 
Bromophenol blue 
CaCl2 
Chloroform 
Cotton swab 
DNA ladder (100 bp) 
DNAladder(lkb) 
DNA ladder (10 kb) 
EDTA 
Ethanol 
Ethidium bromide 
Genomic DNA isolation kit 
Glacial acetic acid 
Glycerol 
Gel extraction Kit 
HiComb MIC Test strips 
Hydrochloric acid 
Isoamyl alcohol 
Lyso2yme 
MgCl2 
NaOH 
Plasmid DNA isolation kit 
PCR master-mix 
Proteinase K 
RNase 
SDS 
Sodium acetate 
kits used: 
SRL, India 
Hi-Media, India 
SRL, India 
SRL, India 
Hi-Media, India 
Genei-Bangalore, India 
Genei-Bangalore, India 
Fermentas, Canada 
SRL, India 
E. Merck, India 
Sigma, USA 
Qiagen, USA 
E. Merck, India 
SRL, India 
Qiagen, USA 
Hi-Media, India 
SRL, India 
SRL, India 
Sigma, USA 
SRL, India 
SRL, India 
Qiagen, USA 
Genei-Bangalore, India 
Sigma, USA 
Sigma, USA 
Hi-Media, India 
SRL, India 
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Tris-saturated Phenol Genei-Bangalore, India 
Tris-HCl E. Merck, India 
Xylene cyanol Bio-Rad, USA 
2.1.2 Culture media: 
Following culture media used for the isolation and identification of the organism was 
purchased from Hi-Media, Pvt. Ltd. Mumbai, India. 
Agar agar 
Brain-Heart Infusion Broth. 
EMB-Broth 
Luria-Bertani broth 
Mac-Conkey agar 
Mueller-Hinton agar 
Mueller-Hinton broth 
Nutrient agar 
Nutrient broth 
Selective media of Hi-crome series (Hi-media, Mumbai, India), which are highly specific 
for single target microorganism each (e.g. Hi-crome Klebsiella selective agar, Hi-crome 
E.coli selective agar) 
2.1.3 Antibiotics: 
All of the following antibiotic discs were purchased from Hi-Media, Pvt. Ltd, Mumbai, 
India. 
Amikacin 
Amoxyclav 
Ampicil 1 in/Sulbactam 
Amoxicillin/Sulbactam 
Aztreonam 
Ak 
Ac 
As 
Ams 
Ao 
30 ^g 
20/10 i^g 
10/10 ^g 
10/10 ^g 
30 Mg 
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Cefaclor 
Cefalothin 
Cefazolin 
Cefepime 
Cefepime/ Tazobactam 
Cefixime/Clavulanic acid 
Cefotaxim 
Cefoxitin 
Ceftazidim 
Ceftazidim/Clavulanic acid 
Ceftriaxone 
Ceftriaxone/Sulbactam 
Ceftriaxone/Tazobactam 
Cefiiroxim 
Chloramphenicol 
Ciprofloxacin 
Co-trimoxazole 
Ertapenem 
Erythromycin 
Gatifloxacin 
Gentamicin 
Imipenem 
Meropenem 
Methicillin 
Norfloxacin 
Oxacillin 
Piperacillin 
Tetracyclin 
Tobramycin 
Cj 
Ch 
Cz 
Cpm 
Cpt 
Cmc 
Ce 
Cn 
Ca 
Cac 
Ci 
Cis 
Cit 
Cu 
C 
Cf 
Co 
Ert 
E 
Gf 
G 
I 
Mr 
M 
Nx 
Ox 
Pc 
T 
Tb 
30 ^g 
30 ^g 
30 ng 
30 ^g 
30/10 ng 
30/10 Jig 
30 ^g 
30 Hg 
30 ^g 
30/10 fig 
30 fig 
30/10 ^g 
30/10 ng 
30 Jig 
30 Jig 
5Mg 
1.25/23.75 Jig 
30 Jig 
15 Jig 
5^g 
10 Jig 
10 Jig 
30 Jig 
5 Jig 
30 Jig 
30 Jig 
100 ^g 
30 Jig 
30 Jig 
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2.2 Methods 
2.2.1 Sample collection and identification of clinical isolates 
Sample of clinical isolates were collected from neonatal intensive care unit (NICU) and 
intensive care unit (ICU) of JNMC hospital, Aligarh, located in north India, which is a 
tertiary care hospital. Clinical samples were collected from different sources (eyelid, 
body surface, nose, pharynx, rectum and instruments etc.). Each patient admitted to the 
ward was weekly examined. Information and history regarding the illness of patients and 
neonates was obtained from patients, parents and consultant of the ICU and NICU. 
Clearance was obtained from the institute's ethical committee held on 6 July, 2009. The 
significant pathogens were identified by standard biochemical procedures [Baron et ah, 
1994]. Strains of ESBL producing E.coli, K. pneumoniae and Pseudomonas isolated from 
surveillance swabs and from clinical samples of the patients and neonates were included 
in the study. All the specimens were identified for the presence of AT. pneumoniae, E.coli 
and Pseudomonas using HiCrome Klebsiella, E.coli and Pseudomonas Selective Agar 
Base identification kit (Himedia, Mimibai, India) and final confirmation of bacterial 
identities was done by 16S rDNA sequencing using the universal primer 27F and 
1525R (Table 2.1). 
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1.1.1 Antimicrobial susceptibility tests, ESBL, MBL detection and determinations 
of MICs ^  ESBL producing strains 
The antimicrobial susceptibility was determined by the standard disc diffusion method 
using Muello" Hinton agar as per the Clinical and Laboratory Stmidards Institute (CLSI, 
2011) guidelines. The antibiotic discs used were obtained from Himedia Laboratories 
Pvt. Ltd., Mumbai, India. The ESBL phenotypic confirmatory test with ceftazidime, 
cephotaxime, ceftriaxone and cefixime was performed for all the probable isolates by 
disk diffusion metiuMJ on Mueller-Hinton agar plates withAvithout 10 mg of amoxyclav. 
A >5mm increase in diameter of inhibition zone with third generation cephalosporins was 
observed, when tested in combination with amoxyclav, showing ESBL production. 
MBL production was detected using combined disc diffusion test by using two 
imip^iem, two meropenem axiA two ertapenem discs (lO^g) with and without 0.1 M 
ethylene diamine tetra acetic acid (EDTA). One containing 292 ng (10 ^l of 0.1 M) 
anhydrous EDTA, which were placed 25 mm apat (center to center) on Mueller Hinton 
agar plate. An increase in zone diameter of >4 mm aroimd the imipenem + EDTA, 
meropenem + EDTA aid ertapenem + EDTA disk compared to that of the imipemen, 
meropenem and ertapenem disk alone was considered positive for an MBL [Khan et al., 
2012]. All ESBL producing s ^ n s were also subjected to undergo minimal inhibit<Hy 
concentrations (MICs) determination using two fold agar dilution susceptibility methods 
acc(»xling to upd^ed CLSI guidelines (CLSI, 2011). Apprt^riate dilutions of p-lactam 
antibiotic solutions were prepared according to the report of international collaborative 
sUidy in which one part of the antimicrobial solution was added to nine parts of liquid 
Muller-Hinton agar. The MIC values were compared witii the break points recommended 
by CLSI. E. coli ATCC25922 was used as ESBL negative and K. pneumoniae 700603 
was used as ESBL positive reference strain. 
2.2.3 Statistical analysis 
Student t-test and Fishers test for univariate analysis were performed to explore the 
potential risk factors for ESBL mid non ESBL producer strains. Odds ratio (OR) and 95% 
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confidence intervals (CI) 95% were also performed. Normally distributed continuous 
vmiable was analyzed using student t-test. The resistance rate was calculated as the 
number of resistant strains divided by the total number of strains. The difference was 
considered statistically significant if p-values were ^ .05 . All p-values were two tailed, 
statistical analysis were performed by Statistical Package for the Social Sciences (SPSS 
Inc. Chicago, USA) version 16.0. 
22.4 Resistance transfer experiments 
To determine the location of the genes on the chromosome or on a plasmid, conjugation 
was done by using selected resistant stiains as donors and Escherichia coli J-53 (EJ-53) 
(resistant to 250 jig of sodium azide), as selective recipient in all conjugation 
expmm^fits. Multi-drug resistant donw strains Mid recipient strain EJ-53 were inoculated 
into nutrient broth separately and incubated at 37°C until the cells reached logarithmic 
growth phase. 200 fil of recipient and 50^1 of d<Hior were then added to 5 ml of fi-esh 
nutrient broth and incubated overnight at 37°C. A loop-fiil of the mixture was then spread 
on the surface of MacConkey agar containing ampicillin (25^g/ml) plus sodium azide 
(250ng/ml) as selective antibiotics. The plates were incubated overnight at 37°C. 
Colonies of EJ-53 ilxaX grew on ihe sodium azide /ampicillin selective plates and again on 
subculture on ampicillin plates were regarded as trans-conjugants, which were further 
charactoized for Uie {M^ esence of resistant makers. 
2 J.5 Extraction and preparation of plasmid DNA 
Plasmid DNAs were extracted by QIAprep Spin Miniprep Kit (Qiagen, USA). One 
colony of «ach s ^ n was inoculated in 5 ml of LB (Luria-Bert£Uii broth) containing a 
suitable concentration of antibiotic for selection, for 18 hours at 37 "C and centrifiiged at 
8,000 vpm for 15 minutes at 4 °C to pellet the cells. The pellets were re-suspended in 250 
\i\ of Buffer PI (50 mM TRIS-HCl, 10 mM EDTA, pH 8.0 containing 100 ^ g/ml RNase 
A). 250 |il of Buffer P2 [200 mM NaOH, 1% SDS (w/v)] was added to the samples, 
mixed thoroughly by vigorously inverting 4-6 times and incubated at room temperature 
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for 5 minutes. Then 350 nl of chilled Buffer N3 (3.0 M potassium acetate, pH 5.5) was 
added to Ae cell lysates, mixed thorou^ly by vigorously inverting 4-6 times and 
incubated on ice for 15 minutes. The samples were centrifuged for 10 minutes at 13,000 
rpm at 4 °C. Hie supematwits attaining the plasmids were applied to the QIAprep spin 
colunms. The columns were washed twice with 0.75 ml of Buffer PE [70% ethanol]. The 
flow-tluwi^ was discarded, and cenfrifogation was done for an aiditional 1 min to 
remove residual wash buffer. The plasmid DNAs were eluted with 50 jil of Buffer EB 
[10mMTris-Cl,pH8.5]. 
2.2.6 Extraction and preparation of total genomic DNA 
Total DNA from strains containing studied plasmids were extracted by QIAamp DNA 
Mini Kit (Qiagen, USA), by the following procedure: one colony from each sti-ain was 
inoculated in 5 ml of LB (Luria-Bertani broth) containing a suitable concentration of 
^itibiotic f<M- selection, for 18 hours at 37 °C. 1 ml of overnight cultures were fransferred 
in a 1.5 ml micro-centrifuge tube and centrifuged at 7500 rpm for 10 minutes to pellet the 
cells. To lyse the cells, the pellets were re-suspended in 180 ^l of Buffer ATL, 20 fxl of 
proteinase K was added, mixed by vortexing, and incubated at 56 °C until the cells were 
completely lysed (lysis is usually complete in 1-3 hours). Vortexing was done 
occasionally during incubation to disperse the sample. 4 jil of RNase Solution (100 
mg/ml) was added to cell lysates, mixed by pulse vortexing fw 15s, and incubated at 37 
°C for 2 minutes. 200 i^l Buffer was added to the RNase-treated cell lysates, vigorous 
v(Mtexing done for 15s and incubation done at 70 °C for 10 minutes. Vnea, 200^1 ethanol 
(96-100%) was added to the sample, and mixed by pulse vortexing. This mixture was 
d)^) ai^lied to the QIAamp Mini spin column with 2 ml collection tube and 
centrifiigation done at 8000 rpm for 5 minutes. The QIAamp Mini spin column was 
placed in a clean 2 ml collecti(Mi tube, and the tube containing the filfrate was discfu'ded. 
500 \i\ Buffer AWl was added and centrifugation performed at 8000 rpm for 2 minutes. 
The columns were washed again with 500 ^l Buff^ AW2 and centrifrtged at 8000 rpm 
for 3 mmutes. The flow-through was discarded, and centrifugation done for an additional 
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1 min to remove residual wash buffer. The genomic DNAs were eluted with 200 \i\ of 
Buffer AE {10 mM Tris-Cl, pH 8.5]. 
2.2.7 PCR amplification and molecular typing 
Analysis of genetic relatedness of the ESBL-producers was done by the standard method 
of Versalovic et al (1991) using the enterobacterial repetitive intergenic consensus 
(ERIC)-PCR. PCR amplification was used to find out the blacvx-u, MOTEU, blosm, 
WfloxA-i WflKPc, WflNDM-i,ArmA and RmtA genes in the isolates which were positive for 
ESBL synergy test. Presence of genes in selected strains was confirmed by genomic and 
plasmid DNA screening. Plasmids were extracted by the Qiagen miniprep kit (Qiagen 
USA). Integrons screening was also performed for the same isolates as described 
previously {Guerra et al., 2000; Galimand et al., 2003]. Briefly, stand^d PCRs were 
carried out in 50 ^L volumes containing 5 jxL of 10 x PCR buffer (100 mM Tris-HCl (pH 
8.8), 500 mM KCl, 15 mM MgClz, 1% Triton X-100), 5 ^Lof 10 x deoxynucleotide 
triphosphate mix (2 mM each dATP, dCTP, dOTP and dTTP) (Sigma,USA.), 2 nL of 
«ach primer stock solution (25 pmol/ftL), 35 jiL sterile distilled water and 1 jiL Taq-
polymerase (1.5 \J/\xL diluted solution) (Sigma,USA), and 2-5 \iL (I00ng-l^g) of 
template DNA. Amplification was perfiMmed in a theraiocycler (Applied Biosystem, 
Veriti, 96-well thermal cycler 9902, Connecticut, USA). The amplification conditions 
used have also been reported previously [Pagm i^ et al., 2003; Doi et al., 2004, Lee et al., 
2006] and the relevant sets of PCR primers are listed in table 2.1. Briefly, PCR conditions 
used for amplification of blacix-u, blur&A, blosm, blooxA-u WAKPC, A/tfNDM-i, ArmA, 
RmtA, integrons, 16S rDNA as well as for ERIC-PCR consisted of the following steps: 
[1] Initial denaturation step of 10 min (95°C) [2] 35 cycles cimsisting of (i) Denaturation 
step of 1 min (95''C) (ii) Annealmg step of 1 min (50°C for blocrx-u, WATEM, WASHV, 
WfloxA-i, W«KPc, W«NDM-i and 16S rDNA; 55°C for AnnA, RmtA integrons and ERIC 
typing) (iii) Extension step of 3 min (72''C) [3] Final extension step of 10 min (72°C) [4] 
Storage at 4°C. 
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2J2.S Agarose gel electrophoresis, staining and visualization of gel 
Plasmid DNA, Genomic DNA or PCR products (25 ^l) were mixed with 2-8 jil of 10 x 
TAB buffer and 1-4 \i\ of Iwomophenol blue (0.25%). The mixtures were applied to 1-
1.5% agarose gels (Sigma, USA) and products separated by electrophoresis for 2-4 h at 
90 V using 1 X TAE running buffer (4.84 g/L Tris, 0.37 g/L EDTA, pH 8). To stain the 
gel after a run, the gel was slid off the platform into a trough containing 0.5ng/ml 
e^idium br<Mnide solution in 1 x TAE buffer and was let to be stain^ for 20-30 minutes. 
The gel was destained in distilled water for 1-2 hours. The DNA samples were visualized 
by placing gel on a UV transilluminator (254-360 nm) and photo^phed using gel 
documentation (Bio-Rad Laboratories, USA), A 100 bp DNA ladder, Ikb DNA ladder 
and DNA mass ruler (Fermentas, C^iada) were included in this study. 
2.2.9 Extraction of DNA from agarose gel 
PCR products (100 ^l) were separated by agarose gel electrophoresis on 1% gels and 
bMids of jM«dicted sizes were cut from tiie gels with minimum exposure to UV 
illumination. The DNA was extracted from the gel slices using a DNA extraction kit 
(Qiagen, USA) by incubation in sodium perchlorate(forexti'acting fragments <500 bp) or 
sodium iodide (for fragments >500 bp) at 55°C for 5 min. Resin (15 iil) was then added 
and the samples were incubated at room temperature for 1 min. After centriftigation at 
16000 X g for 30 sec, the pellet was re-suspended in 1 ml washing solution, followed by a 
1:1 dilution with 99% ethanol. Hie sample was again centriftiged at top speed for 30 s 
and the supernatant was discarded. The pellet was incubated at 55°C (tube with open lid) 
until all the alcohol had evap<»Bted. Sterile distilled H2O (10 ^l) was added to the pellet 
after 1 min incubation at room temperature followed by centriftigation for 30s then the 
supernatant containing the DNA was collected in fresh tube. The final step was repeated 
to yield approximately 20 \il of DNA sample. 
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2.2.10 Sequencing of genes 
Sequencing of Ae genes was performed using the same primers whidi were used for PCR 
amplifications (Table 2.1). DNA sequences were performed on an ABI 3130 Genetic 
Analyzer (Applied Biosyst«ns). 
2.2.11 PCR-based replicon typing/Incompatibility 
Total DNA was obtained from non transconjugants and was subjected to PCR based 
replic(Mi typing for the identificati<Mi of major plasmid inc<Mnpatibility groups among 
Enterobacteriaceae. The plasmid DNA from the non transconjugants were amplified by 
five multiplex and three simplex PCRs using 18 pairs of primers listed in table 2.1 that 
recognized toe replicons FLA, FIB, FIC, HIl, HI2,11-1, L/M, N, P, W, T, A/C, K, B/0, 
X, Y, F, and FIIA [Carattoli etal, 2005]. 
2.2.12 Multilocus sequence typing (MLST) 
MLST is used for the identification and classification of K. pneumoniae clinical isolates. 
The candidate loci sequences were obtained from die strains rpoB (beta-subunit of RNA 
polymerase), gapA (glyceraldehyde 3-phosphate dehydrogenase), mdh (malate 
dehydrogenase), pgi (phosphoglucose isomerase), phoE ^hosphorine E), infB 
(translation initiation factor 2) and tonB (periplasmic energy transducer) and subjected to 
MLST. The PCR ^nplifications of the different MLST target genes were performed 
using 1.5 mM MgCla, 200 mM of dNTP's, 25-50 ng template DNA and the relevant sets 
of PCR primers jue listed in table 2.1 using thermo cycler (Aj^lied Biosystem, Veriti, 
96-well thermal cycler 9902, Connecticut, USA). Amplification parameters included an 
initiai den^uratiim at 95°C fi>r 2 min followed by 35 cycles of amplification comprising 
of de-naturation (95°C for 1 min), annealing (temperature of 50°C for all genes except for 
g«pA (60°C) and tonB (45 °C) and primer extension steps 72°C for 2 min and a final 
extension of 5 min at 72°C. All the amplified fragments were checked on 1.5% or 2% 
agffl-ose gel witii ethidium bromide staining and the amplicons were sequenced in both 
the directions using ABI 3130 genetic analyzer sequencers (Applied Bio-systems). 
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The analysis of sequences obtained for each gene fragment was performed using MLST 
walysis website (ht^://www.pasteur.fr/recherche/genopole/PF8/mlst/kpneumoniae.btml) 
For each fragment, the sequences obtained from the clinical strains were compared and 
alkk numbers were assigned to each unique sequence. Each isolate was defined by the 
combination of numbers corresponding to the alleles at the loci analyzed, which is an 
allele profile or sequence type (ST). Sequences differeirt even at a single nucleotide site 
were considered distinct alleles. 
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3.1 Introduction 
Enterobacteriaceae have become one of the most important causes of hospital and 
community acquired infections [Canton et ah, 2008]. Since 2000, most countries in 
Europe have experienced a rapid increase resistance in Enterobacteriaceae harboring 
extended spectrum ^-lactamases (ESBLs) [Coque et al., 2008]. This increase in resistance 
can be largely explained by the dissemination of E. coli, K. pneumoniae and 
pseudomonas carrying P-lactamases [Livermore et al, 2007]. ESBLs are the bacterial 
enzymes that impart resistance against advanced generation cephalosporins. There is a 
widespread occurrence of ESBLs, particularly in hospital environment [Paterson et al, 
2005;Pfallere/a/.,2006]. 
ESBLs are dangerous because they are plasmid associated and there can be cross species 
dissemination of these plasmids. Moreover, these plasmids can carry genes for co-
resistance to other antibiotics such as aminoglycoside, fluoroquinolones, tetracyclines, 
chloramphenicol and sulfamethoxazole-trimethoprim. Antibiotic selection for such 
isolates thus becomes a therapeutic challenge. The widespread clinical use of broad 
spectrum ^-lactam antibiotics has led to a marked increase in the incidence of ESBL 
producing gram negative microbes [Ma et al, 2009; Shakil et al, 2010]. The majority of 
ESBLs are derived from the widespread broad spectrum ^-lactamases TEM-1 and SHV-1 
[Wright et al, 2005, Gazouli et al, 1998]. However, the prevalence of occurrence of 
these organisms varies significantly in different geographical regions. CTX-Ms are a 
class of ESBLs that are name after the antibiotic 'cefotaxime'. CTX-Ms have become the 
most prevalent ESBLs worldwide [Rodn'guez-Bafio et al, 2010], but have most often 
been associated with focal outbreaks in Eastern Europe, South America, Southeast Asia-
Japan and recently in India with many variants described [Rodriguez-BaAo et al, 2006; 
Akram et al, 2011].CTX-M type ESBL are mainly found in Escherichia coli strains and 
CTX-M producers are exteemely common in UTIs [Akram et al, 2007]. The CTX-M-15 
enzyme in particular is increasingly being reported among E.coil isolates from northern 
India. In view of this background we have initiated this study to characterize the bacterial 
pathogens in patients having gram negative septicemia. Further, to evaluate the 
antimicrobial resistance and underlying molecular mechanisms in these strains. The 
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present study was undertaken; to assess the prevalence of plasmid mediated ESBL spread 
in Medical ICU of a teaching hospital in North India. 
3.2 Experimental outline 
The present study was conducted in Interdisciplinary Biotechnology Unit of AMU, India 
in collaboration with the department of Medicine, of a tertiary care teaching Hospital 
Aligarh, India. Inclusion criteria: patients having clinical features and bacteriological 
evidence of sepsis, septic shock, multi-organ dysfunction and/or systemic manifestation 
of gram negative septicemia. Exclusion criteria: Immunocompromised, patients with 
disseminated TB, HIV and patients on steroids were excluded from the study. Informed 
written consent was given by all study subjects and the study was approved by 
Institutional Ethics committee. Study design: Prospective, observational, non-
interventional study. Isolation and identification of microorganism: On admission 
appropriate culture: urine, sputum, pus, urinary catheter tip, tracheal aspirate was sent in 
vial using standard techniques. Standard methods for isolation and identification of 
bacteria were used throughout the study [Sutter et al., 1985]. The identified bacteria were 
also confirmed by the selective media of the Hi-crome series (Hi-media, Mumbai, India). 
Antimicrobial susceptibility testing of the isolates was performed by the CLSI standard 
disc diffusion method as outlined in section 2.2.2. The ESBL phenotypic confirmatory 
test was performed for all the probable ESBL-producers as mentioned in section 2.2.2. A 
search for bla CTX-M, bla SHV and blajBA gene was made among E.coli, Klebsiella spp. and 
Pseudomonas using both plasmid and genomic DNA and typing was performed by 
ERIC-PCR, as outlined in section 2.2.7. Conjugation studies for marker transfers were 
also carried out on these strains by both matting method as described in section 2.2.4. 
33 Results 
Total 70 patients with mean age of 55.94 ± 10.77 years, predominantly men (70%) and 
women (30%) were studied. On clinical evaluation, urinary tract (61.4%) was the most 
common site of infection, followed by respiratory tract (28.6%) skin and soft tissue 
(10%). The most common organism encountered for sepsis was E.coli 41(58.6%) 
followed by Klebsiella spp. 23(32.9%) and Pseudomonas 6 (8.6%). In patients having 
urosepsis most common organism responsible was E.coli 35(81.4%) followed by 
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Klebsiella spp. 6(14%) and Pseudomona 2(4.6%). In patient having pneumonia with 
sepsis the most common organism encountered was Klebsiella spp. 15 (75%) followed by 
Pseudomona 4(20%) and Exoli 1(5%). In patients having diabetic foot with sepsis in the 
study group most common organism encountered was E.coli 5(71%) followed by 
Klebsiella spp. 2(28.6%).The most common co-morbidity was diabetes mellitus 35 
(50%), followed by benign Prostatic Hypertrophy 10(14.3%) and Chronic Obstructive 
Airway Disease 3(4.3%) (Table 3.1). 
In the study group, E.coli, Klebsiella spp and Pseudomonas found to be resistant to 
gatifloxacin in 31.7%, 17.4% and 66.75% patients respectively. E.coli, Klebsiella spp and 
Pseudomonas were found to be resistant to the amikacin in 43.9%, 69.6% and 16.7% 
patients respectively. Rcoli showed 7.3% intermediate resistance to amikacin. All the 
three organisms were 100% resistant to ampicillin and co-trimoxazoie. E.coli and 
Pseudomonas showed 0% resistance to imipenem on the other hand Klebsiella spp. 
Showed 4.3% resistance. E.coli, Klebsiella spp and Pseudomonas were found to be 
resistant to meropenem in 9.7% and 50% patients respectively. E.coli and Klebsiella spp 
showed intermediate resistance to meropenem in 4.8% and 47.8% patients respectively. 
Most of the gram negative organisms are sensitive to imipenem and meropenem. Almost 
all gram negative organisms (E.coli, Klebsiella spp and Pseudomonas) were resistant to 
co-trimoxazole. (Table 3.2) 
In the present study 7.3% E.coli isolates showed ESBL production while 12.2% E.coli 
showed MBL production on the other hand Klebsiella spp and Pseudomonas showed no 
ESBL/MBL production. In the present study majority of the isolates encountered for 
gram negative sepsis was E.coli (58.6%) and 81.4% E.coli were isolated from patients 
having urosepsis. 
In the present study only 3 (7.3%) E. coli strains had a phenotype consistent with 
production of an ESBL. These 3 E. coli isolates were screened for the presence of 
ceftrixone hydrolyzing ^-lactamases (CTX-M) and WarEMand bla^m types by PCR using 
universal primers. Three isolates (lIE-59, UE- 61, and UE -64) showed the presence of 
blajEM, and MOCYX-U type enzyme, while all the three were found negative for blasm 
(Figure 3.1 & 3.2). Furthermore, conjugation experiments using J-53 as recipient 
susceptible cells confirmed that these markers are present on plasmid. 
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Figure 3.1. PCR ampiificatioi of hlactx-M gene. Lane M: DNA ladder, Lane P: Positive 
caitrol. Lane 1-3: E. coli clinical isolates (UE-59, UE-61, and UE-64) LaneN: Negative 
control. 
0.1 Kb 
Figure 3.2. PCR amplification of A/OTEM gene. Lane M: DNA ladder, Lane P: Positive 
control. Lane 1-3: £. coli clinical isolates (UE-59 and UE-64) Lane N: Negative control. 
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3.4 Discussion 
Gram-negative sepsis is a significant problem in hospitalized and community- dwelling 
patients. Although the percentage of hospital-acquired bloodstream infections (BSls) 
associated with gram-negative bacilli has decreased, these organisms now pose serious 
therapeutic problems because of multidrug resistance [Suarez etal., 2005]. 
The treatment of gram-negative bacteremia is increasingly complicated by the occurrence 
of multidrug resistant gram negative bacilli strains. Over production of chromosomal fi-
lactamases by Enterobacter spp. has become one of the most common mechanisms of 
resistance to third generation cephalosporins [Goossens et al., 2005]. In our study group 
most common organism encountered for sepsis was E.coli 41(58.6%) followed by 
Klebsiella spp. 23(32.9%) and Pseudomonas 6(8.6%). Similar results for the most 
common isolates were identified in community acquired sepsis in an Italian study: E.coli 
(76%); P. aeruginosa (7.9%); K. pneumoniae (5.4%); Proteus mirabilis 4.2%; 
Enterobacteriace species 3.7 percent [Luzzaro et al., 2002]. UTI remains the commonest 
type of community acquired gram negative sepsis, especially in developing countries. A 
similar study has been performed earlier where Taylor et al showed most common 
organisms responsible for nosocomial urosepsis were E.coli (36.8%) and Pseudomonas 
8.9% [Taylor et al., 1996]. In our study most common organism isolated from patients 
having pneumonia was Klebsiella spp. 15(75%) followed by Pseudomonas 4(20%) and 
E.coli 1(5%). A similar study done by Feldeman et al who found 31.9% isolates were 
Klebsiella spp and 8,9% were Pseudomonas [Feldman et al., 1995]. In the present study 
E.coli, Klebsiella spp and Pseudomonas were found to be 100%, 95% and 100% 
respectively resistant to cefazolin and cefiiroxime. For ceftazidime, Ecoli was found to be 
100% resistant, Klebsiella spp. Showed 91,4% resistance and Pseudomonas showed 
83.3% resistance. Our findings are comparable to study conducted by Kumari et al 
[Kumari et al., 2007]. In the present study 7.3% E.coli isolates showed ESBL production 
on the other hand Klebsiella spp and Pseudomonas showed no ESBL/MBL production. 
While MBL production was seen in 12.2% E.coli. Extended spectrum ^-lactamase 
(ESBL) and metallo P-lactamase (MBL) production is a matter of great concern in the 
field of microbial drug resistance. ESBL represents a major threat among resistant 
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bacterial isolates of Enterobacteriaceae [Paterson et al., 2005].This renders powerful 
antibiotics, like expanded spectrum cephalosporins, carbapenems and monobactams 
ineffective. India has significantly high pool of ESBL infection, reflecting poor standards 
of hygiene and inappropriate use of antibiotics, as compared to other developed societies. 
The source of ESBL producing Enterobacteriaceae differ, while in other countries it is 
mainly hospital acquired, in India it is mostly community acquired [Canton et al., 2008]. 
Different groups of ESBLs, have been described and classified according to their amino 
acid sequences, like SHV-l, TEM-2, TEM-3 etc. Until the end of the 1990s, most of the 
ESBLs detected were SHV and TEM types, mostly associated with nosocomial outbreaks 
[Livermore et al., 2005]. In 1989 simultaneous detection of ESBLs producers have been 
identified in different country of Europe. CTX-M was named because most of the 
enzymes within this family confer resistance predominantly to cefotaxime rather than 
ceftazidime [Eckert et al., 2006]. The CTX-M ESBLs have since been detected in many 
species of Enterobacteriaceae, currently the CTX-M family includes more than 100 
vairents which may be grouped on the basis of sequence similarity in to 4 distinct 
subtypes epitomized by CTX-M-1, CTX-M-2, CTX-M-8, and CTX-M-9. The Atocrx-M-is 
gene borne on plasmid in Enterobacteriaceae, was first detected in India, which is now 
the globally dominant ESBL [Walsh et al., 2007]. Unlike in other countries e.g. Spain, 
France, where members of multiple CTX-M lineages have been reported, a virtually 
absolute prevalence of the members of the CTX-M-1 lineage was observed in this study 
[Cant6n et al., 2006]. Recent reports have shown a rapid and alarming dissemination of 
Enterobacteriaceae producing ESBLs of the CTX-M type in certain counties including 
India and have become the most prevalent ESBL type worldwide [Walsh et al., 2007]. 
The majority of these isolates are now recovered from community patients, most of them 
with urinary tract infection [Eshwar^pa et al., 2011]. Unlike that of TEM or SHV type 
ESBLs, the population structure of CTX-M producing isolates is complex and is 
associated with the spread of specific plasmid and /or other mobile genetic elements 
rather than clonal epidemics [Mendonca et al., 2007]. 
Bacterial resistance to commonly used antibiotics, in a resource crunched developing 
country like India, threatens the basic health delivery systems, affecting millions. There 
are alarming reports about serious consequences of antibiotic resistance. However, there 
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is Still a scarcity of data on the magnitude of antibiotic resistance, especially in Asia-
Pacific region. 
3.5 Conclusion 
This woric has provided insights into molecular epidemiology of escalating antimicrobial 
resistance, especially prevalent in ESBL producing Enterobacteraceae in India. 
Continueing surveillance will be necessary to monitor the evolution of ESBL and to 
authenticate whether the CTX-M type ESBLs will eventually prevail over the WajEM-
type ESBLs, which are still widespread, especially in some areas. Our findings uphold 
the increasing role of the WACTX-M p-lactamases in antibiotic resistance and stress upon 
the significance of appropriate empirical treatment for infections caused by coliforms, 
especially during septicemia. This study confirms that horizontal gene transfer of 
antimicrobial resistance markers is the most prevalent among Enterobacteraceae in the 
community setting. Further studies are needed, however, to determine whether antibiotic 
policies or other measures can halt or lower the level of horizontal gene transfer that 
occurs in a hospital or community setting. 
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4.1 Introduction 
Extended spectrum ^lactamase (ESBL) producing Klebsiella pneumoniae constitute one 
of the most common Gram negative bacteria showing multiple antibiotic resistances 
worldwide [Livermore et al. 2007]. However, there is an epidemiological change in the 
community over the last 20 years with the emergence of virulence. An increasing 
prevalence of extended spectrum ^-lactamase producing Klebsiella pneumoniae (EPK) 
was reported during the past decade as reported by Centers for Disease Control and 
Prevention National Nosocomial Infection Surveillance study, particularly in intensive 
care unit (ICUs) [ Fridkin et al, 1999]. ESBLs (Jblacrx-u^ A/ATEM and blasm) producing 
K pneumoniae strains are spread throughout hospital settings, and become predominant 
in the community [Jacoby et al., 1997; Cabrera et al., 2009]. The worldwide spread of 
resistant gene marker is facilitated by horizontal gene transfer mechanisms. Antibiotic 
selection for such infective strains thus becomes a therapeutic challenge. Outbreaks by 
ESBL producing organisms have been described frequently in NICU settings [Mirelis et 
al., 2003]. Clinical conditions and treatments predisposing to infection by such pathogens 
have been investigated but very few studies were able to identify independent risk factors 
and there is a paucity of ESBLs data concerning neonates, particularly in India. In view 
of the present situation, we initiated our study to understand the mode of mechanism 
among the K. pneumoniae isolates, circulating in NICU, Aligarh hospital of north India 
and to identify the various risk factors associated with acquisition of these infections 
caused by ESBL producers. 
A2 Experimental outline 
Analysis of different risk factors like socioeconomic status, educational status and 
epidemiological like gender, mode of delivery, age, gestational age, birth weight (patients 
prior to infection, and severity of illness), maternal anemia, maternal intrapartum 
symptomatic infections (was define as receipt of at least 1 dose of antibiotic therapy 
during labor and considered an opportunity to provide antibiotics when mother was in the 
hospital after the risk condition and at least 1 hour before delivery), leaking per-vagina, 
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bleeding per-vagina, prolonged rupture of membrane unclear vaginal examination of 
mother, infection carriage (throat, nasal, eyelid, and urinary catheter at the time of 
infection), length of hospital stay before the onset sepsis in NICU and included 
instruments (mechanical ventilator, radiant wormer, phototherapy, cot, stethoscope, 
refrigerator and weighing machine). Patients selected for analysis were those admitted in 
the active surveillance system (NICU stay >48 h and weekly surveillance swabs taken at 
least once). Neonates admitted to the ward before January 2006 and discharged after 
February 2009 was excluded. A total of 18 risk factors were analyzed. Descriptive 
analyses were used for socioeconomic status, educational status and epidemiological data 
in terms of percentage between two groups of patients. Student t-test and Fishers test for 
univariate analysis were performed to explore the potential risk factors for ESBL and non 
ESBL producer strains. Odds ratio (OR) and 95% confidence intervals CI (95%) were 
also performed as mentioned in section 2.2.3. Normally distributed continuous variable 
was analyzed using student t-test were appropriate. The resistance rate was calculated as 
the number of resistant strains divided by the total number of strains. The difference was 
considered statistically significant if p-values were ^ .05 . All p-values were two tailed 
and statistical analysis was performed by Statistical Package for the Social Sciences 
(SPSS Inc. Chicago, USA) version 16.0. 
Bacterial identifications were confirmed as mentioned in the previous study (Chapter 3). 
Antimicrobial susceptibility testing of the isolates was performed by the CLSI standard 
disc diffusion method as outlined in section 2.2.2. MICs of cephalothin, cefazolin, 
cefuroxime, cephoxitine, ceftriaxone, ceftazidime, cefotaxime and cefepime were 
determined by the CLSI microbroth dilution method. The ESBL phenotypic confirmatory 
test was performed for all the probable ESBL producers as mentioned in section 2.2.2. A 
search for W«CTX-M, blaxEM and blasiw genes and integrons was carried out using the 
primers consisted of following oligonucleotide specific primer in table 2.1 made among 
these strains using both genomic and piasmid DNA and typing was paformed by ERIC-
PCR, as outlined in section 2.2.7. PCR-based replicon typing was carried out on 11 non-
conjugative and conjugative plasmids. The 18 sets of primer (Table 2.1) were used to 
target HIl, HI2,11-ly, X L/M, N, FL\, FIB, W, Y, P, FIC, A/C, T, FIIAs, F, K and B/0 
replicons (incompatibility) were used in separate PCR reactions described elsewhere 
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[Elhani et al., 2010]. MLST was done according to the protocol described in section 
2.2.12 and sequence typing was analyzed according to the site 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/kpneumoniae.htmI) on 4 isolates of 
K. pneumoniae selected on the basis of ERIC and replicon typing. Sequencing was done 
as mentioned in section 2.2.10. Traismissibility of biocrx-u markers was checked by 
conjugation as described in section 2.2.4. 
4J Results 
A total of 3500 neonates that were screened for the infection in NICU over the period of 
3 yerars, 970 (27.71%) were found to have clinically suspected culture, while 365 (37.62 
%) of them were positive for neonatal infection. Among 365 clinical isolate, 103 (28.21 
%) were EPK while 262 (71.78 %) were non EPK. 
Of 103 EPK strains, 64 (62.13%) isolates of K pneumoniae were found in low 
socioeconomic status group. Whereas, 25 (24.27%) and 14 (13.95%) were observed 
among middle and upper income group respectively (Table 4.1). Among 103 isolates of 
ESBL carriers, 37 (35.92%) were illiterate, 47 (45.63%) were literate and 19 (18.44%) 
were educated. On the basis of sex ratio, among these ESBL producers, 79 (76.69%) 
were male and 24 (23.20%) of them were found among females. Furthermore, the study 
also revealed that, 72 (69.69%) case were found to be cesarean while remaining were 
normal births. A total of 76 (65.04%), age wise ESBL carriage were observed among the 
neonates of 0-5 days whereas, 36 (34.95%) were present in the neonates of 6-30 days. 
Our study further revealed that on the basis of gestational period, 81 (78.64%) ESBL 
producers were observed as preterm babies and 22 (21.35%) as term babies. 
Classification based on onset sepsis reveled 80 (77.66%) isolates as early onset sepsis and 
23 (22.33%) isolates as late onset sepsis. The preset study also showed that according to 
the birth weight, 62 (60.19%) clinical isolates were obtained from neonates weighing less 
than 1500g whereas, 41 (39.80%) neonates were of more than 1500g. Our data showed 
that occurrence of EPK in maternal anemia, maternal intrapatum symptomatic infection, 
leaking per vagina, bleedmg per vagina, prolonged rupture of membrane, and unclear 
vaginal examination of mother were 38 (36.89%), 11 (10.67%), 11 (10.67%), 12 
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(11.65%), 21 (20.38%), 43 (41.74%), and 70 (67.96%) respectively (Table 4.1). During 
the study period, 25 (24.27%), 37 (35.92%), 7 (6.70%) and 20 (19.21%) EPK were 
responsible for infection carriage in throat, nasal, conjunctivitis and urinary tract 
infection (UTI) respectively. Furthermore, neonates staying for 1-5 days in hospital, 
showed 66,99% of infection while neonates staying for 6-30 days in the hospital showed 
33.00% infection (Table 4.1). Of 103 EPK isolates fi-om NICU, 30 (29.12%) isolates 
were of environmental origin. These 30 isolates were distributed among, ventilator, 
radiant wormer, phototherapy, cot, stethoscope, refrigerator and weighing machine with 
distribution figures, 2 (1.94%), 4 (3.88%), 7 (6.79%), 9 (8.73%), 5 (4.85%), 1 (0.97%) 
and 2 (1.94%) respectively (Table 4.1). 
A total of 365 isolates of K. pneumoniae were recovered during the study period. 
Comparative susceptibility test among EPK and non EPK with antibiotics (Table 4.2) 
revealed that ESBL positive isolates of K. pneumoniae (EPK) had significantly higher 
resistance against these antibiotics. In EPK, our study demonstrated that, higher and 
lowest percent of resistant strains were observed against penicillin (86.40%) and 
pipracillin (57.28%) respectively among the P-lactum groups (Table 4.2). Moreover, 
79.61% and 32.03% resistance was observed against tobramycin and amikacin 
respectively. Our study further revealed that among the fluoroquinolone, highest and 
lowest percent resistance was observed against nalidixic acid (84.46%) and gatifloxacin 
(27.18%), respectively. Furthermore, susceptibility testing of these isolates revealed 
highest resistance against cotrimoxazol and tetracycline. A total of 43 (41.75%) EPK 
strains were found resistant against cefepime (Table 4.2). Some of the EPK isolates from 
neonates of various risk status, shared resistance against meropenem. 
EPK strains isolated from NICU, showed presence of multiple plasmids of different 
molecular size (Table 4.3). Among 103 EPK isolates with two or three plasmids, the 
presence of small size transferable plasmids (28 kb) was detected in 21 (20.38%) EPK. 
74 (71.84%) of these EPK strains harbored a conjugative mega plasmid. These mega 
plasmids bear gene imparting resistance against extended-spectrum cephalosporins. The 
transconjugants were also detected for their susceptibility against various antibiotics of P-
lactam, aminoglycoside and fluroquinolone group using disk diffusion test and 
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microdilution method. The tranconjugants showed multidrug resistance (MDR) 
phenotype including resistance to all generation of cephalosporine. 
ERIC-PCR was performed for the analysis of molecular characterization of K. 
pneumoniae strains which categorized 103 strains in 11 different phylogenic groups 
(Figure 4.1). Also, the 11 stains fix)m each phylogenic group were further confirmed by 
ERIC-PCR as shown in figure 4.2. The A5 group was most frequently observed among 
the isolates (26 of 103 strains, 25.24%). The types of ESBL producing K. pneumoniae 
are summarized in table 4.1. Of 103 K. pneumoniae cases 19 had WflcTx-M-3, 28 had 
WflTEM-i and 17 were found to have WtfsHv-i type ESBLs. Integrons were also detected in 
all 11 strains with a consistent size of 530bp (Figure 4.3), representing each phylogenic 
group and was found as class I integron carrying Int-\ (Figure 4.4) and 5M/-1 (Figure 4.5) 
genes of the expected sizes 845bp and 840bp, respectively. Amplified products for each 
blocrx-u (Figure 4.6), blarEM (Figure 4.7), and A/OSHV (Figure 4.8) were sequenced and 
analyzed using NCBI data base site (http/www.ncbi.nlm.nih.gov/).The plasmids carrying 
the WacTX-M-3 WATEM-I and WflsHv-i genes were assigned to Inc/H12 (Figure 4.9), Inc/X 
(Figure 4.10) Inc/FIC (Figure 4.11), and Inc/FIB (Figure 4.12) replicon types. MLST 
analysis of 4 isolates revealed 3 different sequence types (STs), whereas, one of them was 
found untypeable (Table 4). Moreover, this analysis also showed dissemination of bla 
crx-M-3, W«TEM-i and bla SHV-I gene through K. pneumoniae clinical isolates of ST-64, ST-
280 and environmental isolate of ST-51 in the NICU (Table 4.4 and figure 4.13-4.19). 
In the univariate analysis of EPK, several study variables like maternal intrapartum 
symptomatic infection, prolonged rupture of membrane, length of stay in NICU and 
Carbapenem use (/*=0.00) were found to be very closely associated with EPK and non-
EPK acquisition status of neonates (Table 4.1). 
Independent risk factors for EPK, included seven different types of variables associated 
with ESBL carriage (Table 4.1) under the socioeconomic status of lower income group 
(p=0.01), illiterate under the educational status (p=0.03), preterm under the gestational 
age (p=0.005), early onset sepsis under the onset sepsis (p=0.02), <1500g under the birth 
weight (p=0.04), nasal (p=0.03), conjunctivitis (p=0.02), UTI (p=0.04) under the 
infection carriage and instrumentation (p=0.03), ampicillin (p=0.02) and penicillin 
(p=0.01) under the P-lactam, amikacine under the aminoglycosides (p=0.04), 
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ciprofloxacin under the fluoroquinolone (p=0.04) as well as gatifloxacine under the 
fluoroquinolone (p=0.03) and cefepime under the cephalosporin 4* generation (p=0.02) 
respectively. We observed that use of 3^** and 4* generation of cephaiosporine and 
carbapenems were signiflcantly associated with infection of ESBL-producing organism 
in the univariate analysis, but no significance was observed in the multivariate analysis 
(Table 4.2). 
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Figure 4.1 ERIC profiles of ESBL producing K. pneumoniae isolates from NICU. M 
stands for marker (tlie first lane of each figure), Al-All represents different ERIC t\ped 
clinical isolates and N stands for negative control (the last lane of each figure) 
Saeedut Zafar Ali, 2012 I Chapter-4 
0.1 Kb 
F^ure 4.2 ERIC profik for reconfirmation of 11 differciit phylogenic groups of 
ESBL producing K. penumoniae in NICU. M stands for mariner (tite first lane of 
each figure), Al-All represents different ERIC tjped clinical isolates and N stands 
for negative control (the last lane of eadi figure) 
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Figire4J PCR amplification of 5'-CS-3'CS conserved sequences of integron. Lane 
M: 10 Kb DNA ladder, lane M l K penumoniae clinical isolates (113,183,229,270, 
277, 295,308,329,332,346,363) and Lane P: positive control. 
M 113 183 229 270 277 295 308 329 332 346 363 
10 Kb 
1.031 Kb 
0.845Kb 
0 5 Kb 
0.1Kb 
Figure 4,4 Integron mapping by PCR amplification of Int-1 gene. Lane M: 10 Kb 
DNA ladder, 1-11 K. penumoniae dinical isolates (113,183,229,270,277, 295, 308, 
329,332,346,363) and Lane P: positive control. 
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Figure 4^ Integron mapping by PCR amplification of Sul-1 gene. Lane M: 10 Kb 
DNA ladder, 1-11K. penumoniae clinical isolates (113,183,229, 270, 277, 295,308, 
329,332,346,363) and Lane P: positive control. 
M 113 183 229 270 277 295 308 329 332 346 363 P N 
10 Kb 
1.031 Kb 
0.5 Kb 
0.1Kb 
0.60 4Kb 
Figure 4.6 PCR amplification of CTX-M gene. Lane M: 10 Kb DNA ladder, 1-11K. 
penumoniae clinical isolates (113,183,229,270,277,295,308,329,332,346,363), 
Lane P: positive control Lane N: negative control 
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M N 113 18.1 229 270 277 295 308 329 332 46 363 P 
10 Kb 
1.031 Kb 
0.5 Kb 
0.1Kb 
<-1.090Kb 
Figure 4.7 PCR amplification of TEM gene, Lane M: 10 Kb DNA ladder, Lane N: 
negative control 1-11 if. penumoniae clinical isolates (113,183,229,270,277,295, 
308,329,332,346, 363), Lane P: positive control 
M 113 183 229 270 277 295 308 329 332 346 
10 Kb 
1.031 Kb 
0.5 Kb 
OJKb 
0.1Kb 
0JI34Kb 
Figure 4.8 PCR amplification of SHV gene, Lane M: 10 Kb DNA ladder, 1-11K. 
penumoniae clinical isolates (113,183, 229, 270,277, 295, 308, 329, 332,346, 363), 
Lane P: positive control Lane N: negative control 
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PI P2 P3 229 N 
Figyre 4.9 PCR amplification of replicon typing. Lane PI (Inc/HIl), P2 (Inc/HI2), 
P3 (Inc/Ily): positive contrd, 1K. penumoniae clinical isolates (229) and lane N: 
negative control 
Figure 4.10 PCR amplification of replicon typing, Lane PI (Inc/L/M), P2 (Inc/X), P3 
(Inc/N): positive control, 1-3 K. penummiae clinical isolates (183, 277 and 346) and 
lane N: negative control. 
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P3 113 
Figiire 4.11 PCR amplification of replicon typing, Lane PI (IncAT), P2 (Inc/P), P3 
(Inc/FIC): positive control and one JiT. penumoniae clinical isolates (113). 
PI P2 P3 270 295 308 329 332 362 
Figure 4.12 PCR amplification of replicon typing, Lane PI (Inc/FIA), P2 (Inc/FIB), 
P3 (IncAV): positive control 1-6 K. penumoniae clinical isolates (270, 295,308, 329, 
332 and 363) and lane N: negative coitrd. 
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346 363 
10 Kb 
0.501Kb 
0.1Kb 
Figure 4.13 PCR amplification of MLST (rpo), Lane M: 10 Kb DNA ladder 1-11 iT. 
penumoniae clinical isolates (113,183,229, 270,277,295,308,329,332,346,363). 
113 183 270 277 308 329 332 .346 363 
0.450Kb 
0.1Kb 
Figure 4.14 PCR amplification of MLST (gap), Lane M: 10 Kb DNA ladder 1-11K. 
penumoniae dinkal isolates (113,183, 229, 270,277, 295, 308,329, 332,346,363). 
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M 113 183 229 270 277 295 308 329 332 346 363 
10 Kb 
1.031Kb 
OiKb 
0.1Kb 
,477Kb 
Figure 4.15 PCR amplification of ML ST (mdh). Lane M: 10 Kb DNA ladder 1-11 K. 
penumoniae clinical isolates (113,183,229,270,277,295,308,329,332,346,363), 
M 113 183 229 270 277 295 308 329 346 363 
0432U) 
Figure 4.16 PCR amplification of ML ST (pg 2), Lane M: 10 Kb DNA ladder 1-11 K. 
penumoniae clinical isolates (113,183,229,270,277, 295,308,329,332,346,363). 
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M 113 183 229 270 277 295 308 329 332 346 363 
1.031Kb 
0.420Kb 
Figure 4.17 PCR amplification of MLST (pho), Lane M: 10 Kb DNA ladder 1-11 K. 
penumoniae clinical isolates (113,183, 229, 270,277, 295, 308, 329,332, 346, 363). 
M 113 183 229 270 277 295 308 329 332 346 363 
0.318Kb 
0.1Kb 
Figure 4.18 PCR amplification of MLST (inf), Lane M: 10 Kb DNA ladder 1-11 K. 
penumoniae cUnkal isolates (113,183, 229, 270,277, 295, 308, 329,332, 346, 363). 
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VI 113 229 270 277 295 308 329 332 346 
10 Kb 
1.031Kb 
0.5 Kb 
0.1Kb 
0.414Kb 
Figure 4.19 PCR amplification of MLST (ton), Lane M: 10 Kb DNA ladder 1-11 K. 
penumoniae clinical isolates (113,183,229,270,277,295,308,329,332,346,363). 
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4.4 Discussion 
K. pneumoniae is frequently associated with nosocomial infection in NICU and the rate 
of multi carriage EPK is higher during the neonatal period than in any time of life. The 
high level of EPK was found among neonates, delivered to mother with lower income 
groups, illiterate and literate showing highest possibility of acquired neonatal infection 
(62.13%, 35.92% and 45.63 %) respectively which is an important findings of this study. 
Our data was consistent with Begum et al (2003) which showed education status of 
mother (OR 2.7) and monthly income of mother belonging to category less than 2000 
rupees (OR 5.05), as significant risk factors for preterm neonates [Begum et al., 2003]. 
Our data was further supported by earlier study which found that the poverty and 
education are the main risk factor for neonatal infection [Perlinot et al, 2011]. 
Predisposition to ESBL-producing enterobacteriace carriage in households where the 
head is unemployed or is an unskilled worker has already been reported in Israel. The 
highest carriage rates were observed for people with low and uitermediate income 
suggesting that poor sanitary conditions favor the transmission of EPK [Ben-Ami et al., 
2006].The possibility of acquiring neonatal infection is 78.64% among preterm and 
21.35% among term babies. This is slightly higher than prevailing condition as reported 
earlier [Riskin et al., 2004]. Preterm babies were found to be a major risk factor for 
nosocomial infection in previous studies [Hagberg et al., 2005]. However, preterm 
neonates delivered by mother of Chorio-amnionitics are more prone to have intra-
ventricular hemorriiage and there by long-term neurological disability. 
Predominance of early onset sq>sis and late onset sepsis is 77.66% and 22.33% 
respectively as shown earlier [Gladstone et al., 1990]. Sepsis is considered to be the 
result of various risk factors, both maternal and neonatal such as prematurity, low birth 
weight, hyaline membrane disease, small gestational age, prolonged amniotic membrane 
rupture of mother and birth defect and asphyxia [Rojo et al, 1999]. No uniform criteria 
have been established yet for sepsis screening of infants at risk of early onset sepsis. 
Among the low birth weight babies, the babies weighing less than 1500 g have the 
highest possibility of acquiring neonatal infection (60.19%) as compared to the neonates 
weighing more than 1500 g [Soman et al, 1985]. Low birth weight has been found to be 
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a great risk factor for nosocomial infection. The main reasons are premature immune 
systems and extended exposure to broad spectrum antimicrobials in low birth weight 
neonates. Cell mediated immunity is greatly suppressed in malnourished babies and have 
a higher incidence of neonatal infection which corroborates with the earlier study [Isaack 
e^fl/., 1992]. 
Risk factors for EPK in NICU have been previously identified by univariate analysis. 
Previously, it was found that duration of hospital stay and early onset sepsis were the 
independent variable associated with rectal colonization along with EPK [Boo et al., 
2005]. Our results partly confirm these findings; total stay in hospital proved to be 
independent risk factors for acquisition, suggesting that the hospital environment play a 
crucial role in the transmission of such pathogens. The prevalence of 41.74% neonatal 
infection was observed in neonates, delivered by mothers having a prolong rupture of 
membrane (more the 24 hours) as also shown previously [Bizzarro et al., 2005]. 
These studies revealed the prevalence of EL pneumoniae infection in nasal (35.92%), UTI 
(19.41%) and conjunctivitis (06.70%), the data was comparable to the most recent 
National Nosocomial Infection Surveillance System (NNISS) data [Gaynes et al., 1996]. 
This is the first study to the best of our knowledge, conducted in north India, for the 
muhi-carriage infection. It was fiarther observed that prevalence of infection carriage of 
EPK in the community was not related to age and sex of neonatal infection, but there was 
significant relation with the isolation of bacteria fix)m medical equipments (like 
ventilator, radiant wormer, photo therapy, cot, stethoscope, refrigerator and weighing 
machine) in NICU (29.12%) which is comparable to the NNISS data (26.6%). 
EPK might be acquired throu^ horizontal gene transfer. Our data demonstrate that EPK 
isolates harbored three plasmids (28kb, 64kb and 154kb) and were able to transfer 
resistance against ce^axone. However, varying sized plasmids (5-185 kb) carrying 
ESBL genes have also been detected in K. pneumoniae in earlier studies [Essack et al., 
2001]. Our data revealed the presence of WacTx-M-3, WOTEM-I and A/OSHVI genes on the 
plasmids which has already been reported earlier in Europe [Livermore et al., 2009]. We 
have detected 11 class 1 integrons which were invariably PCR positive for int-\ and sul-
1, also demonstrated earlier [Khemtong et al., 2008]. In accordance to our data, hospital 
dissemination of ESBLs caused by the horizontal transfer of large conjugative plasmids 
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carrying ESBL producing genes has also been described earlier in both pediatric and 
adult intensive care unit [Miranda et al., 2004]. 
In the present study EPK isolate from NICU showed Inc/FIC, Inc/H12, Inc/X and 
Inc/FIB replicon types of plasmids (Table 4). This has already been shown earlier in 
which plasmids of Inc/HI2 and Inc/FIB were associated with the W«CTX-M-3 and WtfiEM-i 
gene deriving from K. pneumoniae [Carattoli et al., 2009]. 
MLST was performed on the basis of ERIC typing and incompatibility and was found 
ST-64 (KP113), ST-280 (KP277) and ST-51 (KP229) as shown in table 4. ST-520 is 
genetically close variant of ST-64; ST 520 is a single locus variant (rpo allele), ST-131 is 
genetically close variant of ST-51; ST-131 is a single locus variant (pho allele) and ST-65 
is genetically close variant of ST-280; ST-65 is also a single locus variant (ton alleles) of 
ST 280. Two clinical isolates (KPl 13, KP229) which were from the different patients and 
one of them was environmental isolate (KP277) in NICU (Table 4). All four EPK STs 
described in tiiie present study indicates that the most of the strains are scattered 
throughout the phylogenetic tree of K. pneumoniae rather than clustered into a single 
genetic lineage which suggest that dissemination of EPK resistance is due to horizontal 
gene transfer [Son et al., 2010]. 
One of the most striking findings in the present study was the high level of resistance to 
third generation cephalosporins among JC pneumoniae isolates. Almost 68% isolates 
were resistant to cefotaxime, ceftriaxone and ceftazidime. The SENTRY surveillance 
program reported the frequency of EPK to be ^proximately 37% in Latin America and 
7% in the United States [Sader et al., 1998]. Within the Asian Pacific region, the 
prevalence of EPK was reported to be 5%, 21.7%, 31% and 38% in Japan, Taiwan, 
Philippines and Malaysia/Singapore, respectively. The present data show resistance 
against multiple group of antibiotic (^lactam, aminoglycosides, fluoroquinolone and 
tetracycline). This is consistent with previous findings [Bizzarro et al., 2007]. In the 
present study, K. pneumoniae isolates were found to be highly resistant to tetracycline 
(78.64%) and cotrimoxazole (91.26%). This is probably due to the fact that this antibiotic 
has been widely used over the past decade in this region because of the low cost and easy 
availability to the poor people residing in various imderdeveloped pockets of the 
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Otherwise developing nation. Similar studies have also been performed in other parts of 
India. Our data have shared harmony to previous reports [Shobha et al, 2007]. 
4.5 Conclusions 
The study concludes that the independent risk factors for EPK infection are low 
socioeconomic status and illiteracy of mother. Moreover, the use of carbapenem, 
Ceftazidime, gatifloxacine, ciprofloxacin and amikacin may enhance the susceptibility of 
EPK. In order to prevent the EPK infection in neonates, avoiding non judicial use of 
antibiotics and common sharing of the unsterilized equipments should not be practiced. 
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5.1 Introduction 
Multidrug resistant gram negative bacteria are a major therapeutic challenge both in NICU 
and hospital settings [Chiu et al., 2000]. These isolates are getting resistant to multiple 
antimicrobial agents, including aminoglycosides, quinolones, extended spectrum 
cephalosporins by hydrolysis of the p-lactam ring and are inhibited by P-lactamase 
inhibitors. There are more than 400 extended spectrum ^-lactamases (ESBLs) described so 
far, mostly derived from the groups CTX-M, TEM, SHV and OXA [Coque et al, 2008]. 
However, these acquisition rates increase dramatically in hospitalized patients in direct 
proportion to the length of stay. Moreover, K. pneumoniae is very well adapted to the 
hospital environment since it exhibits higher survivability on hands and environmental 
surfaces than other member of Enterobacteriaceae [Haque et al., 2011]. Such infections 
mainly concern with the patients admitted to NICU with several co-morbidities and a 
history of prolonged administration of antibiotics [Pena et al., 2007]. On the other hand, 
simultaneous production of OXA-1 P-lactamase is poorly inhibited by clavulanic acid, 
tazobactam or sulbactam and has negligible activity against first-generation 
cephalosporins [Poirel et al, 2004]. Antibiotic selection for such infective strains thus 
becomes a therapeutic challenge. Outbreaks by ESBL producing organisms have been 
reported frequently in NICU settings [Mirelis et al., 2003]. Clinical conditions and 
treatments predisposing to infection by such pathogens have been investigated but very 
few studies were able to identify the prevalence of K. pneumoniae producing ESBLs in 
NICU and there is a paucity of ESBL data concerning neonates, particularly in India. In 
view of the present situation, we initiated our study to understand the mode of mechanism 
among the K. pneumoniae isolates, circulating in NICU of a teaching hospital of North 
India. 
5.2 Experimental outline 
The present study was previously described in section 2.2.1. Antimicrobial susceptibility 
testing of the isolates was performed by the CLSI standard disc diffusion method as 
outlined in section 2.2.2. The ESBL and MBL phenotypic confirmatory test was 
performed as mentioned in section 2.2.2. MICs of monobactam, cephalothin, cefazolin, 
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cefiiroxime, cephoxitine, ceftazidime, cephotaxime, cefepime, imipaiem, ertapenem, 
meropenem and aztreonam were detennined by the CLSI microbroth dilution method. 
A search for blacrx-u, MOTEM, W«SHV, WaoxA-i, WAKPC, WtfNDM-i.ArmA and RmtA genes 
and integrons were carried out using oligonucleotide specific primers as listed in table 2.1 
for both genomic and plasmid DNA. Molecular typmg was performed by ERIC-PCR, as 
outlined in section 2.2.7. PCR-based replicon typing was carried out on 15 non-
conjugative plasmids as described in chapter 4. 
53 Results 
A total of 3000 neonates that were screened for the nosocomial infection in the NICU, 785 
(26.16%) were found to have clinically suspectwl culture. In which, antibiotic 
susceptibility test was performed to detect 262 (33.37 %) ESBL producing K. pneumoniae 
isolates. 
Antibiotic susceptibility test were performed for all ESBL producing K. pneumonia 
isolates (Table 5.1). ESBL positive isolates of K. pneumoniae were found to have 
significantly higher resistance against these antibiotics. Our study showed that among the 
^lactum groups, higher percent of resistant strains were observed £^ainst penicillin 
(95.80%), followed by pipracillin (91.22%). Highest resistance was observed against 
cephalothin and cephazolin in first generation of cephalosporin group. The pattern of 
resistance among the second generation of cephalosporins that is cefuroxime and 
cephoxitin, were 207 (79.00%) against cefuroxime and 199 (75.95%) against cephoxitin. 
Resistant strains against ceftriaxone were found to be 171 (65.26%). Moreover, in the 
present study it was found that, 86.78% K. pneumoniae strains showed resistance against 
aztreonam. A total of 78 (29.77%) ESBL producing K. pneumoniae strains were found 
resistant against cefepime (Table 5.1). Highest percent resistance was observed against 
gentamicin (74.80%) whereas, 43.12% Kpneumoniae strains were found to be resistant 
against amikacin (Table 5.1). Among the resistance against fluoroquinolones, highest 
percentage of resistance was observed against nalidixic acid (80.53%), while the 
resistance against gatifioxacin was found to be 38.54%. The susceptibility of these isolates 
was also investigated against cotrimoxazol, tetracycline and oxacillin and they showed 
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higher percentage of resistance (Table 5.1). Moreover, the resistance against amoxyclav, 
ampicillin/sulbactam,amoxicilIin/sulbactam,cefixime/clavulanicacid,ceJEtazidim/clavuIanic 
acid, ceitriaxon/sulbactam, ceftriaxon/tazobactam and cefqpime/tazobactam was found to 
be 92.74%, 86.78%, 72.13%, 59.92%, 53.43%, 52.67%, 49.61% and 49.61% respectively. 
In addition, some of the ESBL producing K. pneumoniae isolates from neonates shared 
resistance against meropenem (Table5.1). ESBL producing K. pneumoniae strains isolated 
from NICU, found to have multiple plasmids of different molecular size (Table 5.2). 
Among 262 ESBL producing K. pneumoniae isolates with two or three plasmids, the 
presence of small size transferable plasmids (28 kb) was detected in 16 (6.10%) ESBL 
producing K. pneumoniae isolates. 246 (93.89%) of them harbored a conjugative mega 
plasmid. These mega plasmids bear gene imparting resistance against extended spectrum 
cephalosporins. The transconjugants were also tested for their susceptibility against 
various antibiotics of p-lactam, aminoglycoside and fluroquinolone group using disk 
diffusion test and microdilution method. The tranconjugants showed multidrug resistance 
(MDR) phenotype including resistance to all generation of cephalosporine. 
ERIC-PCR was performed for the molecular characterization of 262 strains of K. 
pneumoniae, which categorized the strains in 15 different phylogenic groups (FigureS.l). 
One strain from each phylogenic group was further confirmed by ERIC-PCR as shown in 
figure 5.2. The Ad group was most fi^uently observed among the isolates (78 of 262 
strains, 29.77%) as shown in figure 5.1. The types of ESBL producing K. pneumoniae are 
summarized in table 5,2. Of 262 K. pneumoniae cases 15 had */acTx-M-j» 13 bad bla^wiA, 
10 had WflsHV-i, 15 had WfloxA-i. 9 had Arm-A and 7 were found to have Rmt-A. Integrons 
were also detected in all 15 strains with a amsistwit size of 5301^ (Figure 5.3), 
representing each phylogenic group and was found as class 1 integrons carrying Sul-\ 
(Figure 5.4) and /«/-lgenes (Table 5.2, Figure 5.5). None of them was amplified for 
A/flKPC, W«NDM-i. Amplified products for each WOCTX-M (Figure 5.6), AtetEM (Figure 5.7), 
WflsHv (Figure 5.8), MOOXAA (Figure 5.9). Arm-A (Figure 5.10) and Rmt-A (Figure 5.11) 
were sequenced and analyzed using NCBI data base site (http/www.ncbi.nlm.nih.gov/) 
replicon types (Table 5.2). 
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Table 5.1 Representation of aDtibiogram 
Antibiotic groups 
Aminoglycosides 
Fluoroquinolones 
p-Lactams 
Others 
Cephaios l^ 'g 
porins 
2"g 
2>''g 
4'^ g 
Carbapenems 
Monobactam 
Inhibitor 
Antibiotics 
combination with 
Inhibitors 
Antibiotics 
G 
Tb 
Ak 
Na 
Cf 
Gf 
A 
P 
Pc 
T 
Co 
Ox 
Ch 
Cz 
Cu 
Cn 
Ca 
Ce 
Ci 
Cpm 
Imp 
Ert 
Mr 
Ac 
Ac 
As 
Ams 
Cmc 
Cac 
Cis 
Cit 
Cpt 
% Resistance to antibiotics 
N«262 (71.78%) 
196(74.80) 
130(49.61) 
113(43.12) 
211(80.53) 
157(59.92) 
101(38.54) 
243(92.74) 
251(95.80) 
239(91.22) 
190(72.51) 
223(85.11) 
190(72.51) 
230(87.78) 
227(86.64) 
207(79.00) 
199(75.95) 
189(72.13) 
178(67.93) 
171(65.26) 
78(29.77) 
00(00.00) 
00(00.00) 
22(08.39) 
227(86.78) 
243(92,74) 
227(86.78) 
189(72.13) 
157(59.92) 
140(53.43) 
138(52.67) 
130(49.61) 
130(49.61) 
Generation (g), Graitamicin (G), Tobramycin (Tb), Amikacin (Ak), Nalidixicacid (Na), 
Ciprofloxacin (Cf), Gatifloxacin (Gf), Ampicillin (A), Penicillin (P), Pipracillin (Pc), 
Tetracyclin (T), Co-trimoxazole (Co), Oxacillin (Ox), Cephalothin (Ch), Cefazolin (Cz), 
Cefuroxime (Cu), Cephoxitin (Cn), Ceftazidime (Ca), Cephotaxime (Ce), Ceflriaxon (Ci), 
Cefepime (Cpm), Imipenem (Imp), Ertapenem (Ert), Meropenem (Mr), Aztreonam (Ac), 
Amoxyclav (Ac), Ampicillin/Sulbactam (As), Amoxicillin/Sulbactam (Ams), 
Cefixime/Clavulanic acid (Cmc), Ceftazidim/Clavulanicacid (Cac), Ceflriaxon/Sulbactam 
(Cis), Ceftriaxon/Tazobactm (Cit),Cefepime/Tazobactam (Cpt). 
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Figure 5.1 ERIC profiles of ESBL producing K. pneumoniae isolates from NICU. M 
stands for marker (tlie first lane of each gel), Aa-Ao represents clinical isolates and N stands 
for negative control (the last lane of first and last gel). 
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Aa Ab Ac Ad Af Af At Ak Al Am An Ac 
1.031 Kb 
Figure 5 ^ E R I C profile for reconfirmation of 15 different phylogenic groups of ESBL 
producing K. penumoniae in NICU. M stands for marker (the first lane of gel), Aa-Ao 
represents clinical isolates. 
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M Kpl9 Kp50 Kp55 KplOS Kpl40 Kpl60 Kpl61 Kpl82 Kp207Kp240 Kp286 Kp290 Kp296 Kji367 Kp375 P 
F igu re 5.3 PCRamplification of 5'-CS-3'CS conserved sequences of integron. Lane M: 10 
Kb DNA ladder, 1-15 K. penumoniae clinical isolates (Kpl9, Kp30, Kp55, KplOS, Kpl40, 
Kpl60, K p l 6 1 , Kpl82, Kp207, Kp240, Kp286, Kp90, Kp296, Kp367, Kp375) and Lane P: 
positive control 
M Kpl9 Kp30 Kp55 KplOS Kpl40 Kpl60Kpl61KpI82 Kp207Kp240Kp286Kp290Kp96 lq)367Kp375 P 
10 Kb 
1.031 Kb 
O.S40Kb 
OiKb 
0.1Kb 
Figure 5.4 PCR Integron mapping by PCR amplification of Sul-1 gene. Lane M: 10 Kb 
DNA ladder, 1-15 K. penumoniae clinical isolates (Kpl9, Kp30, Kp55, KplOS, Kpl40, 
Kpl60, Kpl61, Kpl82, Kp207, Kp240, Kp286, Kp290, Kp296, Kp367, Kp375) and Lane P: 
positive control. 
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M Kpl9 Kp30 Kp55 Kpl08 KpHO Kpl60 Kpl61Kpl82 Kp207 Kp240 Kp286 Kp290 Kp96 Kp367 Kp375 P 
10 Kb 
l.D31Kb 
l)i45Kb 
OiKb 
0.1Kb 
Figure 5.5 Integral mapping by PCR amplification of Int-1 gene. Lane M: 10 Kb DNA 
ladder, 1-15 AT. penmnoniae clinical isolates (Kpl9, Kp30, Kp55, Kpl08, Kpl40, Kpl60, 
Kpl61, Kpl82, Kp 207, Kp240, Kp286, Kp290, Kp296, Kp367, Kp375) and Lane P: positive 
control. 
VI K|>19 Kp3OKpSSKpl08KpI4OKpl60KpieiKpl$2Kp2O7Kp24OKp286Kp29OKp2MKp367Kp37S P \ 
10 Kb 
1.031 Kb 
0.!Kb 
0.1Kb 
0.«0 4Kb 
Figure 5.6 PCR ampUfication of CTX-M gene. Lane M. 10 Kb DNA ladder, 1-15 K. 
penumoniae ctinicn] isolates (Kpl9, Kp30, Kp55, Kpl08, Kpl40, Kpl60, KpI61, Kpl82, Kp 
207, Kp 240, Kp 286, Kp290, Kp296, Kp367, Kp375), Lane P: positive control Lane N: 
negative control. 
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M N Kpl9 Kp30 KpSS KplOS Kpl40 Kpl82Kp207 Kpj40 Kp2g6 Kp290Kp296 Kp3<7 Kp375 P 
1.931 Kb 1.090 Kb 
Figure 5.7 PCRamplification of TEM gene, Lane M: 10 Kb DNA ladder, Lane N: negative 
control 1-14 A^ . penumoniae cUnical isolates (Kpl9, Kp30, Kp55, Kpl08, Kpl40 , Kpl82, 
IQ)207, Kp240, Kp 286, Kp290, Kp296, Kp367, Kp375), Lane P: positive control. 
M Kp30 Kp55 Kpl08 Kpl60 KplSi Kp286 Kp290 Kp29t Kp367 1^ 375 P 
10Kb 
1.031Kb 
0.5Kb-
O.lKb 
234Kb 
Figjire 5.8 PCR amplification of SHV gene. Lane M: 10 Kb DNA ladder, Lane N: negative 
control 1-14 K. penumoniae clinical isolates (Kp30, Kp55, Kpl08, Kpl60, Kpl82, Kp286, Kp 
290, Kp 296, Kp 367, Kp 375), Lane P: positive control and Lane N: negative control. 
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M Kpl9 Kp30 Kp55 KplOS Kpl40 Kpl60 Kpl61 Kpl82 Kp207 Kp240 Kp286 Kp290 Kp296 Kp367 Kp375 P > 
0.440Kb 
Figure 5.9 PCR amplification of OXA-1 gene, Lane M: 10 Kb DNA ladder, 1-15 A', 
pammowioecUnical isolates (Kpl9, Kp30, Kp55, Kp 108, Kpl40, Kpl60, Kpl61, Kpl82, Kp 
207, Kp 240, Kp 286, Kp 290, Kp 296, Kp 367, Kp 375), Lane P: positive control Lane N: 
negative control. 
M Kp30 Kp55 KplOS Kpl4(l Kpl60 Kplg2 Kp286 Kp290 Kp375 
0.1Kb 
Figure 5.10 PCR amplification of Arm-A gene. Lane M: 10 Kb DNA ladder, 1-9 K 
penumoniae clinical isolates (Kp30, Kp55, Kp 108, Kpl40, Kpl60, Kpl82, Kp 286, Kp 290, 
Kp 375), LaneN: negative control. 
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M iq>30 Kp55 Kpl40 Kpl82 Kp290 Kp296 Kp375 N 
0.1 Kb 
Figure 5.11 PCR amplification of Rmt-A gene, Lane M: 10 Kb DNA ladder, 1-7 A'. 
penumoniae clinical isolates (Kp30, Kp55, Kpl40, Kpl82, Kp290, Kp296, Kp375), Lane N: 
negative control. 
PI P2 P3 Kpl9 Kpl61 Kp286 Kp207 Kp240 Kpl82 Kp367 Kp375 
FigMre 5.12 PCR amplification of replicon typing, Lane PI (Inc/HIl), P2 (Inc/ffl2), P3 
(Inc/Ily): positive control, 1-8 K. penumoniae clinical isolates (Kpl9, Kpl61, Kp286, Kp207, 
Kp240, Kpl82, Kp367, Kp375). 
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PI P2 P3 Kpl08Kpl60 N 
Figure 5.13 PCR amplification of replicon typing. Lane PI (Inc/FIA), P2 (IndFIB), P3 
(Inc/W): positive control, 1-2 A', penumoniae clinical isolates (Kpl08, Kpl60) Lane N: 
negative control. 
PI P2 P3 Kp55 Kpl08 KpUO Kpl60 Kp290 Kp296 
Figire 5.14 PCR amplification of replicon typing. Lane PI (Inc/FIA), P2 (Inc/FIB), P3 
(Inc/W): positive control, 1-7 A', penumoniae clinical isolates (Kp30, Kp55, Kpl40, Kp290, 
Kp296). 
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5.4 Discussion 
K. pneumoniae has become one of the most important causes of nosocomial and 
community acquired infections. Aminoglycosides, P-laetams mainly extended spectrum 
cephalosporins and carbapenems (amikacin, cefepime, and carbapenem) constitute the 
main therapeutic choices to treat infections caused by these pathogens in NICU, JNM 
College and hospital, Aligarh. However, resistance to these compounds has been 
increasingly reported from different parts of the world in recent years [Cant6n el al., 
2008]. Among the 262 K. pneumoniae strains, 15 were multidrug resistant (MDR) (i.e. 
resistant to three classes of antimicrobial agents like P-lactam, aminoglycosides, 
fluoroquinolones and cepalosporins. In one of this studies carried in Malaysia, the rate of 
MDR K. pneumoniae strains was found to be 53% which was consistent to our study 
[Manchanda et al., 2005]. 
The present data shows the resistance against third generation cephalosporins among K. 
pneumoniae isolates. 86.64% isolates of K. pneumoniae were found to be resistant to 
cefazolin, 79.00% to cefuroxime, 67.93% to cephotaxime and 65.26% resistant to 
ceflriaxone. It could be due to some other resistance mechanism such as lack of 
permeation of porins and AmpC P lactamase production. Our data are comparable to 
earlier studies [Mohamudha et al., 2010]. The higher proportion of resistant to 
tetracycline (72.51%) and cotrimoxazole (85.11%) is mainly due to widely used 
antibiotics over the past decade in this region. Similar studies have also been reported in 
other parts of the country. Our data have also shared harmony to previous reports 
[Shobhae/fl!/.,2007]. 
Our study revealed the high prevalence of increasing resistance to inhibitors like 
amoxyclav and antibiotics in combination with inhibitors among JC pneumoniae isolates. 
92.74% isolates of K. pneumoniae were found to be resistant to amoxyclav, 86.78% to 
ampicillin/sulbactum, llAWo to amoxiciltin/sulbactum, 59.92% to cefixime/clavulanic 
acid and 49.61% to cefepime/tazobactam. This is consistent with previous finding that K. 
pneumoniae, overproduction of either TEM or SHV increased resistance to amoxicillin-
clavulanic acid and to cephalothin [Petit et al., 1992]. Findings of present study revealed 
that, among the 15 ESBL producing K. pneumoniae strains, all are positive for blacxx-u 
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and btaoxA-] whereas, 10 for 6/asHv and 13 for WOTEM. The presence of multiple ESBL 
encoding genes in K. pneumoniae has also been reported by Romero et al in 2007. His 
study had also reported the co-existence of W«CTX-M-I5 and blaoxA-i plomero et al., 2007]. 
Our data demonstrate that ESBL producing K. pneumoniae isolates from NICU showed 
WflCTX-M, WtfTEM. blasm and WfloxA-i association in the same strain (Table 3). The blacrx-
M-isand blaoxA-i association in the same strain has also been reported in USA [Hradecka 
et al., 2008]. 
In the present study, the percent resistance against aminoglycoside was 55.85% while 
43.12% isolates shared resistance against amikacin. These amikacin resistant isolates 
were found to possess 16s RNA methylase gene and 53.33% of these isolates exhibited 
high level of amikacin, whereas, 40% of isolates represent amikacin, ciprofloxacin, 
gatifloxacin, cephotaxime, ceftazidime and cefepime MDR phenotype indicating 
significant effect of 16s RNA methylases on the emergence of amikacin resistant strains 
among the ESBL producing K. pneumoniae isolates. Our studies are comparable to the 
study conducted by Corvee et al (2009). 
The resistance to P- lactamase inhibitors has been improved by the combined production 
of CTX-M and OXA enzymes in E. coli and K. pneumoniae. This presumably explains 
their non-susceptibility to amoxicillin/clavulanate [Livermore et al., 2005] ESBLs 
producers is becoming a serious clinical problem for the clinician and physician to treat 
infection. In this study, aminoglycosides, fluoroquinolone, P lactam, cephalosporin and 
monobactum resistant genes were found to transfer through horizontal gene transfer in all 
the tested clinical isolates. CTX-M producing isolates were found resistant to cefepime 
(MIC value ranging 7.81^g/ml). The cefepime is hydrolyzed by CTX-M with higher 
efficiency than other ESBL types [Mshana et al, 2009]. 
Plasmid analysis revealed that majority of the transconjugants harbored large plasmids of 
154kb, 64kb and 28kb. In earlier studies blocxx-u gene was reported to be present on the 
varying range of plasmid (7 to 200 kb) [Baudry et al, 2009]. Our study also revealed 
varying sized plasmids carrying MOCTX-M and other resistant markers which are co-
transferred during conjugation among the K. pneumoniae isolates. 
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ERIC typed strains (Ab, Ac, Ad, Ae, Af, Ah, Ak, Al, Am, An and Ao) were subjected to 
undergo replicon typing. Five (IncAly, Inc/FIA-FIB, Inc/FIB, Inc/HI2 and Inc/HIl) 
different replicon types were identified, carrying WOCTX-M-S WATEM-I, W«SHV-I and WOOXA-I 
genes which have already been shown in earlier studies [Pe'rez el al., 2009; Poirel el al., 
2007; Novais el al, 2006 & Hradecka et al., 2008]. 
5.5 Conclusions 
This study concludes polyclonal dissemination of ESBL producing strains among clinical 
isolates ofK. pneumoniae in a teaching hospital of north India. Moreover, this study also 
suggests carbapenem, ceftazidime and amikacin as the drugs of choice for the present 
community. Furthermore, efforts are needed to promote the proper use of antibiotics and 
to discourage their sale over the counter. 
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6.1 Introduction 
Diabetic foot ulcer is the most alarming health problem in India and is expected to 
increase to million populations by 2025 [Abdul el al., 1999]. It has also been reported 
that 15% of diabetic patients would develop a foot ulcer during the course of their disease 
[Boulton et al., 2004]. Neuropathy and impaired blood supply in combination with 
deformities of the feet and the resulting increased pressures on areas of the sole are the 
most important pathophysiological factoid. Though, diabetic foot infection is a broader 
term that includes many pathologies but the most conmion form of diabetic foot infection 
is diabetic foot ulcer which mainly results from neuropathy, ischemia and other complex 
mechanism [Lipsky et al., 2004]. In diabetic foot ulcer protective layer of skin is 
breached and the underlying soft tissues were exposed, thus, providing a better media for 
bacterial colonization [Schubert & Heesemann., 1995]. Infection of diabetic foot ulcer by 
Staphylococcus has been predominantly observed [Xu et al., 2007; Yates et al, 2009]. 
Pseudomonas aeruginosa [Martfnez-G6mez et al., 2009], E. coli [Varaiya et al, 2008], 
Klebsiella species [Goldstein et al, 2008], Enterococcus species [Martinez-Gomez et al, 
2009], and Proteus species [Raja et al, 2007] have also been reported in various diabetic 
foot ulcer cases. 
The recent emergence of antibiotic resistance m bacterial pathogens, both nosocomial ly 
and in community is very serious development that threatens the end of the antibiotic era 
[Rodriguez-Bano & Navarro., 2008; Shakil et al, 2008; Peterson & Bonomo., 2005] 
.More than 70% of the bacteria associated with hospital acquired infections in United 
States are resistant to one or more of the drugs previously used to treat them [Levy & 
Marshall,, 2004]. The rise in multi drug resistance organism attracted the world wide 
biomedical researchers as the available treatment has higher degree of failure and high 
morbidity associated with the infection [Gupta & Stamm., 2002; Sobel & Kaye., 2004. 
Also, several studies support the prevalaice of extaided spectrum p-lactamase (ESBL) 
producing multidrug resistant gram negative bacteria in diabetic foot ulcer. Appearance 
of multiple ^-lactamases in same clinical isolates becomes a challenge for clinicians and 
researchers as it is more difficult to detect the causative resistance factors in multidrug 
resistance pathogens [Karen Bush & Jed F. Fisher., 2011]. However, p-Lactams are still 
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the drug of choice for serious infective condition and the most active of these are the 
carbapenems, which are specially prescribed in ESBL producing pathogen mediated 
infection like Escherichia coli and Klebsiella pneumonic^ [Young et al., 2009]. 
The metallo-p-lactamases (zinc dependant carbapenemases) are bacterial enzymes which 
hydrolyze the carbapenems owing to resistance to the ^lactamase inhibitors but become 
inhibited by metal ion chelators like EDTA. Most of these enzymes hydrolyze the 
cephalosporins and penicillins. Monobactam was found to be susceptible in MBL 
producing K pneumoniae isolates. The most common metallo-P-lactamase families 
include the VIM, IMP, GIM, and SIM enzymes that are located within a variety of 
integron structures, where they have been incorporated as gene cassettes. When these 
integrons become associated with plasmids or transposons, transfer between bacteria is 
readily facilitated. A new subgroup of metallo-^-lactamase (MBL), designated as New 
Delhi metallo-P-lactamase (NDM-1), originating fh)m New Delhi, India which was first 
reported from a Swedish patient of Indian origin who travelled to New Delhi, India, and 
acquired a urinary tract infection caused by a carbapenem resistant K. pneumoniae strain 
[Yong et al., 2009]. There are several reports about the occurrence of NDM-1 MBL 
producing bacterial isolates in many parts of the world but mostly they represent the 
bacterial population of Indian origin [Bratu et al, 2005; Da Silva et al, 2002; Danel et 
al., 1997; Ambler et al., 1991; Gibb et al., 2002; Naas et al, 1994; Bratu et al., 2005]. 
Various works has been carried out to explore and to characterize the MBL producing 
bacterial isolates but there is no study regarding acquisition of MBL producing isolates in 
diabetic foot ulcerated patients. Therefore, this study was carried out to identify the 
multiple P-lacatmase specially, MBL producing bactoial isolates in diabetic foot 
ulcerated patient admitted to the endocrinology ward of Aligarii hospital, a tertiary care 
hospital of north India. The study aimed to determine the resistance and susceptibility of 
those isolates, and to characterize the mode of transmission of blacrx-M, WATEM, W«SHV, 
WflNDM-i, W«oxA and ArmA, among the MBL producing clinical isolates from infected 
diabetic foot ulcers. 
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6.2 Experimental outline 
Twenty diabetic patients having clinically infected foot ulcers admitted to the 
endocrinology ward and ICU at the J. N, Medical College and hospital, Aligarh, over a 
period of i year (April 2010 to November 2011) were studied in a consecutive series. 
Wagner classification was employed to grade the ulcers [Wagner, 1981]. If a patient had 
multiple ulcers, specimens from all the ulcers were taken; and the patient was grouped in 
the multidrug resistance gram negative bacteria (MDRGNB) infected category if any of 
the ulcers was found to be MDRGNB positive. Informed consent was obtained from all 
subjects, and clearance was obtained from the institute's ethics committee. Culture 
specimens were obtained at the time of admission, after the surface of the wound had 
been washed vigorously by saline, and followed by debridement of superficial exudates. 
Specimens were obtained by scraping the ulcer base or the deep portion of the wound 
edge with a sterile curette. The soft tissue specimens were quickly sent to the laboratory 
and processed for microbial pathogens, which were identified as outlined in section 2.2.1. 
Final confirmation of bacterial identities was done by 16S rDNA sequencing as 
mentioned in section 2.2,1. Antimicrobial susceptibility testing of the isolates was 
performed by the CLSI standard disc difftision method as outlined in section 2.2.2. The 
ESBL and MBL phenotypic confirmatory test was performed as mentioned in section 
2.2.2. MICs of Monobactam, cephalodiin, cefazolin, cefuroxime, cephoxitine, 
ceftazidime, cephotaxime, cefepime, imipenem, meropenem, ertapenem, dorapenem, 
colistin, tigecyclin and aztreonam were determined by the CLSI microbroth dilution 
method. A search for blocrx-u^ W«TEM, WffsHv,W«oxA-i,*AiNDM-i and Arm-A genes was 
performed by PCR amplification. The presence of insertion sequences (IS) known to be 
associated with 6/aNDM-i in Enterobacterial isolates from endocrinology ward of Aligarh 
hospital, were confirmed by using oligonucleotide specific primers as listed in table 2.1 
for both genomic and plasmid DNA. PCR-based replicon typing was carried out on 2 
non-conjugative plasmids as described in chapter 4. MLST was performed according to 
the protocol described in section 2.2.12. Transmissibility of WACTX-M, */«TEH biasm. 
blooxA], blotfOM-i and Arm-A markers were checked by conjugation as described in 
section 2.2.4. Sequencing was done as mentioned in section 2.2.10. Gen Bank accession 
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numbers of the KP 12 and EC 15 genes sequenced in this study are JN680194.1 and 
JN860195.1, respectively. 
6.3 Results 
Twenty diabetic patients having clinically infected foot ulcers admitted to the 
endocrinology ward at the J. N. Medical College and hospital, Aligarti, over a period of 1 
year (April 2009 to November 2010) were studied. Among those, 14 (70%) were K. 
penumoniae, 5 (25%) were E. coli and one (5%) was E. cloacae. Of 14 X. penumortiae, 
one clinical isolates was carbapenem (imipenem, meropenem, ertapenem and dorapenem) 
resistant whereas the single E. cloacae strain was also carabapenem resistant. AH clinical 
isolates were found to be resistant to ^-lactam groups (100%), ammoglycoside (90%), 
fluoroquinolones (75%), cephalosporin (71%), other p-lacam antibiotics (81%) and 
carbapenem group (21%). Monobactam group were found to be susceptible against these 
isolates (100%). 
Minimum inhibitory concentrations of P-lacatm, aminoglycoside, 1**, 2"^ , 3*^^ and 4* 
generation of cephalosporins and carbapenem were observed to be 250ng/ml, 7.81-250 
jig/ml, 15.625-250^g/ml and 1.95-31.25jig/ml, respectively (Table 6.2). Colistin and 
tigecycline were found to be susceptible to these isolates (Table 6.2). 
PCR amplification and sequence analysis of DNA fir>m these clinical isolates, using 
primers as described previously (Table 2.1), revealed the presence of W«CTX-I5, (Figure 
6.1) 6/asHv-i (Figure 6.3) in all clinical isolates, blormA-i (Figure 6.2) in 12 isolates (9 
isolates or 75% in K. pmtunoniae, 2 isolates or 16.7% in E. coli and one isolate or 8.3% 
in E. clocace) and bloaxA-i (Figure 6.4) in 7 isolates (5 isolates or 71.4% in K 
pneumoniae, one isolate or 14.3% in E. coli and one isolate or 14.3% in E. clocace). 
/^0N£M-i (Figure 6.6) was identified in £cl5 and Kpl2 strain only. In addition, a 16s 
rRNA methylase gene (Arm-A) was also detected in 5 clinical isolates (Figure 6.5) (4 
isolates or 80% in K. pneumoniae and one isolate or 20% in E. clocace). No blaoxA-4s, 
blovMf, blayfm or WaKPc genes were amplified fi*om these isolates. After the PCR 
amplification, Kpl2 and Ecl5 were identified as blomyux producer isolates and subjected 
for fiirther study. Conjugal transfers were performed using Kpl2 and Eel5 isolates 
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(Figure 6,7). Three types of transconjugants were obtained for Kpl2 and two types were 
obtained for Eel5, according to their resistance phenotypes. One of the transconjugants 
of Kpl2 showed ESBL and NDM-1 producing phenotypes, second transconjugant 
showed only an ESBL producing phenotype and the third showed only the NDM-1 
producing phenotype. Eel5 transconjugants showed two types of phenotypes, one 
displaying an ESBL and NDM-1 producing phenotype and the other displaying a NDM-1 
producing phenotype. Tests using a PCR based replicon typing method (PBRT) revealed 
that the blatmM.\ carrying plasmid in Eel5 was of incompatibility group Inc L/M (Figure 
6.9, Table 6.3), whereas the plasmid in Kpl2 carrying the blafnmi determinant was 
found untypeable. Multilocus sequence typing (MLST) was performed for Kpl2 (Figure 
6.8), as described earlier which was found to be of the type ST14. Primers targeting the 
IS element Abal25 identified a remnant of ISAial25 upstream of the /^ONDM-I gene in 
the Eel 5, whereas an entue ISA6al25 element was identified upstream of the MONDM-I 
gene in the Kp 12 (Figure 6.10). A bleomycin resistance gene bleMBL was identified 
downstream of the A/ONDMI gene in both cases (Figure 6.11). 
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Table 63 Genetic analysis of NDM-1 and other resistant marker on piasmids 
S.no Resistance marker ISAba125 MeMBL ST-Type Plasmid carrying MSNOM-I 
Kpl btecTx-15, Uasm-i, M> Tat^ i 
Kp2 btocTx-is, b/ksHv-1, Ma(»cA-i 
Kp3 blacn-K, MlSHV-1, M> TEM-I 
Kp4 blacna, Masm^i, Ma TBI^I Arm-A 
Ep5 btocTx-is, btesHv-i 
Kp6 /)tecnx-is,M>9HV-i, AteTEi»i 
Kp7 btocix-is, M>sw-i, btooxA-i 
Kp8 bfacTx-is, Masm^i, MKMA-I 
Ep9 MatTx-fs, MtSHV't 
KpIO Macix-is, btosHv-i 
Epil Maox-is, btosH\M. Ms TEM-I 
M2 Mam-is, MasHv-1, MBTEM-1 MaoxA-i, MiM>iff.Ann-A -*- + ST-14 Unable to type by PBRT method 
Kpl 3 blacn-M, MasHv t^, MaoxA-i ,Arm-A 
Kp14 btocTx-is, MasHv-1, bltittn 
E d S MacTx-is, MasHv-i, dteiEM-i MaDXA-1, MsMQif f, Ann-A Truncated + IncL/M 
Kp16 MacTx-is, MasHv-1, MtTEM-1 
Kp17 blacn-K, b/tosm-i, Ma TEM-I 
Ep18 MacTx-is, 6<BSHV-I, A/aoxA-i 
Kp19 MacTx-15, MbsHv-1, Ma TE»I . Ann-A 
Et>20 Macix-15, MasHv-i, Ma TEM I^ 
+, Positive; -, not determined; ST, sequence type; Inc, incompatibility. 
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I ^ i > t^i N 
Figure 6.1 PCR amplification of Wacix M gene. Lane 1-20 clinical isolates of diabetic 
foot ulcer (Ep20, Kpl9, Epl8, Kpl7, Kpl6, Ecl5, Kpl4, Kpl3, Kpl2, Epll, KplO, 
Ep9, Kp8, Kp7, ^ 6 , Ep5, Kp4, Kp3, Kp2, Kpl), Lane P: positive control Lane N: 
negative control and Lane M: 1 Kb DNA ladder, 
M N P Kpl Kp3 Kp4 Kp6 Epll Kpl] Kpl4 EclS Kpl6 KpH Kpl9: 
Figpre 62 PCR amplification of A/OTEM gene. Lane M: 1 Kb DNA ladder, Lane N 
negative control. Lane P: positive contrd and 1-12 clinical isolates of diabetic foo 
ulcer (Kpl, Kp3, Ki>4, Kp6, Epll, Kpl2, Kpl4, EclS, Kpl6, Kpl7, Kpl9, Ep20). 
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^ V^  ^^ 4f^  <v^  -^ ^ ^ '^ ^ ^ ''* ^ ^^ 
Figure 6.3 PCR amplification of A/asm gene, Lane M: 1 Kb DNA ladder, Lane N: 
negative control. Lane P: positive control and 1-20 clinical isolates of diabetic foot 
ulcer (Kpl,Kp2, Kp3, Kp4,Ep5, Kp6, Kp7, Kp8,Ep9, KplO, Epll, Kpl2, Kpl3, 
Kpl4, Ecl5,Kpl6, Kpl7,Epl8, Kpl9, Ep20). 
M N P Kp2 Kp] Kp8 Kpl2 Kpl3 Ecl5 Epl8 
Figure 6,4 PCR amplification ofblaoxxi gene, Lane M: 1 Kb DNA ladder. Lane N: 
negative control. Lane P: positive control and 1-7 clinical isolates of diabetic foot 
ulcer (Kp2, Kp7, Kp8, Kpl2, Kpl3, Ecl5, EplS). 
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M Kp4 1^ )12 Kpl3 EclS Kpl9 P 
846bp 
Figure 6 5 PCR amplification of Arm-A gene, Lane M: 1 K b DNA ladder , Lane N: 
negative conti'ol, lane 1-5 clinical isolates of diabetic foot ulcer (Kp4, K p l 2 , K p l 3 , 
Ecl5, Kpl9) and lane P: positive control. 
Kpl2 Ecl5 P 
Figure 6.6 PCR amplification of NDM-1 gene, lanel-2 clinical isolates of diabetic 
foot ulcer (Kpl2, Eel5), lane P: positive control and lane N: negative control. 
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l M - 1 CTX#I5 TEM-I NDM-I CrX-M-15 SHV-I TEM-1 CDi-.«-15 TEM-1 SHV-I 
Figure 6,7 PCR amplification of resistant marliers obtained from Kpl2 and Ecl5 to 
confirm the transfer of markers by transconjugation. 
400 bp 
300 bp 
200 bp 
Figure 6.8 PCR amplification of MLST profile of KP12 strain from clinical isolate 
(diabetic foot ulcer). The gel shows lane mdh, pgi, pho, InfB, rpo, gapA, to/iB with 
their corresponding molecular sizes 477bp, 432bp, 420pb, 318bp, SOlbp, 450bp and 
414bp respectively. 
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Ecl5 P N M 
SOObp 
lOObp 
Figure 6.9 PCR amplification of Incompatibility (L/M) profile from clinical isolate 
(diabetic foot ulcer). Lane 1 (EclS clinical isolates), lane P: positive contrd and lane 
M; 1Kb marker. 
Ecl5 Kpl2 P N M 
1Kb 
800 bp 
500bp 
ISkba 125 
Figure 6.10 PCR amplification of ISAAfll25 profile from clinical isolate (diabetic 
foot ulcer). Lane 1-2 (EclS, Kpl2 clinical isolates^ lane P: positive control and lane 
M: 1Kb marker. 
Kpl2 EclS P 
blemi 
Figwre 6.11 PCR amplification of AfeMBL profile from clinical isolate (diabetic foot 
ulcer). Lane 1-2 (EclS, Kpl2 clinkal isolates), lane P: positive control and lane M: 
1Kb marter. 
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6.4 Discussion 
Infective diabetic foot ulcer is the most common single precursor to amputation and has 
been identified as a component in 85% of lower exfremity amputations [Margolis et al., 
2005]. Over 20-40% diabetic wounds have been found to be MRSA infected by many 
studies [Shanker et al, 2005; Tentolouris et al, 2006]. Multi drug resistance becomes a 
worldwide problem for clinicians as well as patients. Appearance of multiple P-
lactamases in same clinical isolates also becomes a more worrisome to clinicians and 
researchers [Karen Bush & Jed F. Fisher., 2011]. Carbapenems are the last resort drugs 
for ESBL producing pathogen mediated infection like Escherichia coli and Klebsiella 
pneumoniae [Young et al, 2009]. 
The present study which was conducted on infective diabetic foot ulcer patient admitted 
in ICU and endocrinology ward of JNMCH, Aligarh revealed that out of twenty clinical 
isolates, 14 were Al pneumoniae, 5 were E. coli and one was E. cloacae. Our study 
demonstrates the higher prevalence of iC pneumoniae in diabetic foot ulcers as compared 
to E. coli and E. Cloacae at JNMCH, Aligarh. 
The identified strains were assessed for resistance behaviour against tfierapeutically used 
antibiotics. Of 14 AT. penumoniae, one cilinical isolate (Kpl2) was carbapenem resistant 
whereas single E. cloacae (Eel5) strain was also carbapenem (imipenem, meropenem, 
ertapenem and dorapenem) resistant All clinical isolates, including Kpl2 and Eel5, were 
found to be resistant to p-lactam (100%), aminoglycoside (90%), fluoroquinolones 
(75%), cephalosporin (71%), other P-lacam antibiotics (81%) and carbapenem group 
(21%). Monobactam group was found to be susceptible against these isolates (100%). 
Our data are comparable with the earlier studies of Mohamudha et al., (2010), Shobha et 
al., (2007) and Sader et al., (1998). 
The present data shows that all clinical isolates were resistant against multiple groups of 
antibiotics (P-lactam, aminoglycosides, fluoroquinolone and cephalosporin). This is 
consistent with previous findings [Bizzarro et al., 2007; Manchanda etal, 2005]. 
In the present study, clinical isolates were found to be highly resistant to ^-lactam groups 
(100%) and aminoglycoside (90%). Resistance of these antibiotics may be justified on 
the basis of cost effect and freely accessibility in local market of this region. Similar 
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Studies have also been carried out in other parts of India indicating the shared harmony to 
our study [Shobha et al, 2007], 
Minimum inhibitory concentrations of P-lacatm, aminoglycoside, 1^, 2™*, 3"^^ and 4* 
generation of cephalosporin and carbapenem in these clinical isolates were observed to 
250^g/ml, 7.81-250 ng/ml, 15.625-250^g/ml and 1.95-31.25 ^g/ml, respectively (Table 
6.2). Colistin and tigecycline were found to be susceptible to these isolates (Table 6.2). 
MICs behaviour of these clinical isolates substantiates our findings in above mentioned 
drug resistance study. 
There are several studies showing the reason and mechanism of resistance of ESBL 
producers isolates to these conventional antibiotics. But resistance of two isolates Kpl2 
and Eel5 to carbapenem group of antibiotics directed our study to explore the possible 
character and mechanism of all clinical isolates. So, metallo-P-lactamase activity was 
carried out in all clinical isolates. And after confirmation of MBL producing activity, 
PCR amplification and sequence analysis of DNA revealed the presence of blacxx-xs, 
blasvN-x in all clinical isolates, blarEM-\ in 12 isolates (9 isolates or 75% in K. 
pneumoniae, 2 isolates or 16.7% in E. coli and one isolate or 8.3% in E. clocace) and 
WfloxA-i in 7 isolates (5 isolates or 71.4% in K. pneumoniae, one isolate or 14.3% in E. 
coli and one isolate or 14.3% in E. clocace). In addition, a 16s rRNA methylase gene 
(ArmA) was also detected in 5 clinical isolates (4 isolates or 80% in K. pneumoniae and 
one isolate or 20% in E. clocace). No blaaxA-4», WOIMP, blovm or bluKpc genes were 
amplified in these isolates, whereas they have been reported previously in 
Enterobacterial isolates fix>m India [Poirel et al., 2011b]. Major finding of PCR 
amplification was Ae presence of 6/<INDM-I in Kpl2 and in Ecl5, therefore, these two 
isolates subjected for further study. 
In conjugal transfer study, three types of transconjugants were obtained for Kpl2 and two 
types for Eel5, according to their resistance phenotypes. One of the transconjugants of 
Kpl2 strain showed ESBL and NDM-1 producing phenotypes, other showed only an 
ESBL producing phenotype and the third showed only the NDM-1 producing phenotype. 
Two types of transconjugants, one displaying an ESBL and NDM-1 producing phenotype 
and the other displaying a NDM-1-producing phenotype, were obtained for Eel5 strain. 
These findings may explore the possible mechanism of carbapenem producers. 
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Plasmid profiling, revealed that Kpl2 harboured three plasmids whereas Eel5 carried 
two plasmids, all ranging from 66 to 154 kb in size. Varying sized plasmid (5-185 kb) 
carrying ESBL genes have also been detected in K. pneumoniae in earlier studies [Essack 
e/a/., 2001]. 
PCR-based replicon typing (PERT) revealed that the NDM-lcarrying plasmid in Eel5 
was of incompatibility group Inc L/M (Table 6.3), whereas the plasmid in Kpl2 carrying 
the NDM-1 determinant was not able to be typed. The study of these isolates showed that 
the gene coding for the widespread resistance determinant Wtfcrx-M-is is not associated 
with the gene coding for MONDM-I on the same plasmid. This finding is comparable to 
previous study conducted by GagUe Cuzon et al, (2010), 
ST 14 type of Kpl2 was identified through Multilocus sequence typing (MLST), which is 
one of the types observed in Indian isolates earlier [Poirel et al., 201 Ic]. ta addition, the 
same ST 14 type was identified in the first NDM-1 producing K. pneumoniae isolate from 
Sweden as well as other isolates with links to contamination in India [Poire! et al, 
201 Ic]. Our data suggest that /^ONDM-I genes benefit transposon location, self-transferable 
plasmids, by facilitating their rapid spread to K. pneumoniae and other bacterial species. 
In both strains the surrounding genetic environment was analyzed for the presence of 
insertion sequences (IS) known to be associated with the A/OMDM-I gene in 
Enterohacteriaceae [Poirel et al., 2011c]. Primers tai^eting the IS element KbaMS 
identified a remnant of ISA6al25 upsfream of the A/ONDM-I gene in the Eel5 isolate, 
whereas an entire ISA6al25 element was identified upstream of the ft/atNPM-i gene in the 
Kpl2 isolate. A bleomycin resistance gene bleMSL was identified downstream of the 
bla^iOMA gene in both cases, which encodes a putative bleomycin (an antitumour drug) 
resistance protein, as reported previously [Poirel et al., 2011c]. These later results 
indicate that conserved structures surrounding the A/ONDM-I gene are present in NDM-1 
producing Enterohacteriaceae isolated from north Indian. 
6.5 Conclusion 
The study provides the information regarding the occurrence of MBL producing clinical 
isolates in diabetic foot ulcer patients in north India. It also revealed the presence of 
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bla^mtAA gene in two clinical isolates, E. cloacae and K. pneumoniae. The present data 
and earlier reports indicate the need to control the dissemination of carbapenemase 
producing Enterobacteriaceae in the hospital setting, as well as in the community. To 
control the spread of carb^enem producers, the development of rapid, cheap and easy to 
handle diagnostic techniques for the identification of carbapenemase producers is 
required. 
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1. The present work has provided significant insight into the molecular epidemiology of 
escalating antimicrobial resistance prevalent in ESBL producing Enterobacteraceae in 
India. 
2. The study concludes that the independent risk factors for EPK infection are low 
socioeconomic status and illiteracy of motiier. 
3. Our findings uphold the increasing role of the Wacrx-M type p-lactamase in antibiotic 
resistance and stress upon the significance of appropriate empirical treatment for 
infections. 
4. It also confirms that horizontal gene transfer is the most prevalent method of acquiring 
antimicrobial resistance markers among Enterobacteraceae in the community setting. 
5. It concludes polyclonal dissemination of ESBL producing strains among clinical isolates 
of AT. pneumoniae in a teaching hospital of north India. 
6. It provides the information regarding the occurrence of MBL producing clinical isolates 
in diabetic foot ulcer patients in north India. 
7 It also revealed the presence of A/ONDM-I gene in two clinical isolates {E. cloacae and K. 
pneumoniae) of diabetic foot ulcer patients. 
8. The present data and earlier reports indicate the need to control the dissemination of 
carbapenemase producing Enterobacteriaceae in the hospital setting, as well as in the 
community. 
9. In order to prevent the ESBL producing K. pneumoniae infection in neonates, non 
judicial use of antibiotics and common sharing of the unsterilized equipments should be 
avoided. 
10. Moreover, the use of carbapenem, ceftazidime, gatifloxacine, ciprofloxacin and 
amikacin may enhance the susceptibility of ESBL producing K. pneumoniae. 
11. To control the spread of carbapenem producers, tiie development of rapid, che^ and 
easy to handle diagnostic techniques for the identification of carbapenemase producers 
is required. 
12. Furthermore, efforts are needed to promote the proper use of antibiotics and to 
discourage their sale over the counter. 
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